NADO ITALIA
antidoping

TECHNICAL DOCUMENT
FOR
TESTING AND INVESTIGATIONS

Implementing the *WADA International Standard for Testing and Investigations*

Version 1.0, in effect as from 1st April 2026

TABLE OF CONTENTS

INTRODUCTION

The *Technical Document for Testing and Investigations* (hereinafter "TD_TI") implements the *WADA International Standards for Testing and Investigations* (hereinafter "ISTI") and it is deemed to form an integral and material part of the NADO Italia's *Anti-Doping Sports Code* (hereinafter "*ADSC*").

Interpretation

Unless otherwise specified, references to Titles and Articles are references to Titles and Articles of the TD_TI.

The Annexes to the TD_TI have the same mandatory status as the rest of the Document.

Terms used in this TD_TI that are defined terms from the *Code* and from the *ADSC* are italicized. Terms that are defined in this or another *WADA International Standard* are underlined.

The comments annotating various provisions of the ISTI are incorporated by reference into the TD_TI, shall be treated as if set out fully herein, and shall be used to interpret this TD_TI.

General Principle

Like the *ADSC*, this TD_TI has been drafted giving consideration to the principles of proportionality, human rights, and other applicable legal principles. It shall be interpreted and applied in that light.

TITLE I TEST PLANNING

ARTICLE 1 TESTING DISTRIBUTION PLAN

1.1 NADO Italia, through the Anti-Doping Controls Committee (hereinafter the "ADCC") plans and implements an Intelligent Testing Program which is proportionated to the risk of doping and that is effective to detect and to deter such practices.

1.2 In order to increase the effectiveness of NADO Italia's testing program, the ADCC annually develops and approves the Technical Document "Risk Assessment" for sports and disciplines subject of its Testing Distribution Plan ("TDP").

1.3 The Risk Assessment and the TDP are developed according to the relevant WADA's documents (e.g. "International Standard for Testing and Investigations" – "ISTI", "Guidelines for Implementing an Effective Testing Programme" and "TDSSA").

1.4 The TDP is monitored, assessed and, if necessary, amended and updated on a regular basis as a result of possible changes in anti-doping circumstances and strategies.

1.5 Test distribution planning is an ongoing process, not a static one. NADO Italia shall review the TDP regularly during the year/cycle and shall adapt it, as necessary, to reflect new information gathered and intelligence developed, and to take into account Testing conducted by other Anti-Doping Organizations.

1.6 The ADCC develops a written strategy for retention of Samples and the documentation relating to the collection of such Samples so as to enable the further analysis of such Samples at a later date in accordance with *Code* Articles 6.5 and 6.6. Such strategy shall comply with the requirements of the International Standard for Laboratories and the International Standard for the Protection of Privacy and Personal Information and shall take into account the purposes of analysis of Samples set out in *Code* Article 6.2.

1.7 To implement the TDP, the ADCC selects the *Athlete*s who are to undergo *Sample* collection procedures, according to the *Target Testing* and Random Selection method.

1.8 Once the *Athlete*s to be subject to testing have been identified and the method of testing has been defined, the ADCC shall arrange for In-Competition or Out-of-Competition Testing to be conducted.

1.9 Testing takes place between 6 a.m. and 11 p.m. unless (i) the *Athlete* included in the national "*Registered Testing Pool*" stipulates a 60-minute timeslot from 5 a.m. or, (ii) valid grounds exist for Testing overnight (i.e., between 11 p.m. and 6 a.m.). Moreover, the fundamental principle set out in WADA Code (the "Code") Article 5.2 is that an *Athlete* may be required to provide a *Sample* at any time and at any place by NADO Italia. Accordingly, an *Athlete* may not refuse to submit to *Sample* collection on the basis that such Testing is not provided for in the NADO

Italia's Test Distribution Plan and/or is not being conducted between 6 a.m. and 11 p.m., and/or that the *Athlete* does not meet the relevant selection criteria for Testing or otherwise should not have been selected for Testing.

1.10 NADO Italia, through the ADCC, shall coordinate their Testing efforts with the efforts of other Anti-Doping Organizations with overlapping Testing Authority, in order to maximize the effectiveness of those combined efforts, to avoid unnecessarily repetitive Testing of particular Athletes and to ensure Athletes competing at International Events are suitably tested in advance.

1.11 All Testing shall be No Advance Notice Testing, save in exceptional and justifiable circumstances set out in ISTI Article 5.3.1 and Article 5.3.7.

1.12 The *Athlete*'s Support Personnel or any other person having a conflict of interests may not be involved in the (i) planning of Testing, (ii) selection of *Athlete*s or (iii) phase of Testing implementation.

ARTICLE 2 REGISTERED TESTING POOL

2.1 The *Registered Testing Pool* ("RTP") includes *Athlete*s that are subject to the greatest amount of Testing and are therefore required to provide whereabouts information in accordance with the provisions of the Article 3 here below and with ISTI Article 4.8.6. *Athlete*s in the RTP are subject to *Code* Article 2.4.

2.2 The NSF/ASD/PSE shall be required to provide full support to NADO Italia during the collection of Whereabouts Information regarding *Athlete*s falling under their jurisdiction.

2.3 The inclusion of an *Athlete* in the RTP implies compliance with whereabouts requirements as laid down by Article here below.

2.4 NADO Italia shall conduct Out-of-Competition Testing on *Athlete*s included in its RTP using the *Athlete*'s Whereabouts information. Testing shall not be limited to the 60-minute time slot provided by the *Athlete*. To ensure Out-of-Competition Testing is unpredictable to the *Athlete*, the ADCC shall also consider other whereabouts information provided e.g., regular activities to test the *Athlete*.

2.5 *Athlete*s under the Testing Authority of NADO Italia and of an International Federation should only be in one *Registered Testing Pool*. While being included in more than one *Registered Testing Pool* is possible, *Athletes* shall only file one set of whereabouts information. If the *Athlete* is included in the International Federation's RTP and in the NADO Italia's RTP, then each of them shall notify the *Athlete* that they are in its pool. Prior to doing so, however, they shall agree between themselves to whom the *Athlete* shall provide their Whereabouts Filings, and that Anti-Doping Organization shall be the whereabouts custodian. Each notice sent to the *Athlete* shall specify that they shall provide their Whereabouts Filings to that Anti-Doping Organization only (and it will then share that information with the other, and with any other Anti-Doping Organizations having authority to conduct Testing on that *Athlete*).

2.6 NADO Italia notifies in writing each *Athlete* designated for inclusion in its RTP, at least, of the following: the fact that they have been included in its RTP with effect from a specified date in the future; the whereabouts requirements with which they shall therefore comply; the Consequences if they fail to comply with those whereabouts requirements; and that they may also be tested by other Anti-Doping Organizations with authority to conduct Testing. NADO Italia gives to each *Athlete* included in its RTP a registered e-mail, for formal notice purposes.

2.7 *Athlete* who has been included in a RTP shall continue to be subject to the *Code* Article 2.4 Whereabouts Requirements unless and until: a) they have been given written notice by NADO Italia that put them in its RTP that they are no longer meet the criteria for inclusion in the RTP; or b) they retire from Competition in the sport in question in accordance with the applicable rules and gives written notice to that effect to each Anti-Doping Organization that put them in its RTP.

ARTICLE 3 WHEREABOUTS INFORMATION

3.1 *Athlete*s included in the RTP shall be required to provide quarterly thorough and accurate personal information concerning his/her whereabouts during the relevant period so that he/she may be always located for the purposes of No Advanced Notice Testing during such period. NADO Italia reviews *Athlete*s Whereabouts Filings to ensure they are submitted in accordance with the following provisions.

In detail:

- FIRST QUARTER (JANUARY/FEBRUARY/MARCH): Whereabouts Information must be notified by the *Athlete* in advance or within and not later than **15 December;**
- SECOND QUARTER (APRIL/MAY/JUNE): Whereabouts Information must be notified by the *Athlete* in advance or within and not later than **15 March**;
- THIRD QUARTER (JULY/AUGUST/SEPTEMBER): Whereabouts Information must be notified by the *Athlete* in advance or within and not later than **15 June**;
- FOURTH QUARTER (OCTOBER/NOVEMBER/DECEMBER): Whereabouts Information must be notified by the *Athlete* in advance or within and not later than **15 September**.

It is understood that if an *Athlete* is included in the RTP during a quarter that has already started (e.g. he/she is notified of his/her inclusion in the RTP on 15 July), then he/she shall be required to provide such thorough and accurate Whereabouts Information as to complete the relevant quarter starting from the day specified by NADO Italia and proceed with the completion of the following quarters according to the time schedule and conditions as outlined in this Article.

Whereabouts Information shall be provided through *ADAMS*.

3.2 If an International or National-Level *Athlete* in a *Registered Testing Pool* retires and then wishes to return to active participation in sport, the *Athlete* shall not compete in International Events or

National Events until the *Athlete* has made himself or herself available for testing, by giving six months prior written notice to his or her International Federation and NADO Italia. WADA, in consultation with the relevant International Federation and NADO Italia, may grant an exemption to the six-month written notice rule where strict application of that rule would be manifestly unfair to an *Athlete*. This decision may be appealed under *Code* Article 13.

3.3 The required information shall include the following data for each day of the following quarter:

a) personal details;

b) a complete mailing address and personal e-mail address where correspondence concerning the *Athlete* may be sent for formal notice purposes. Any notice or other document sent to the aforesaid address shall be considered as received by the *Athlete* within 7 (seven) working days of its mailing and immediately when notification of a sent registered e-mail is generated/obtained; it is understood that NADO Italia transmits the formal communications on the registered email given according to the Article 2.6;

c) specific confirmation that the *Athlete* understands that their Whereabouts Filing will be shared with other Anti-Doping Organizations that have authority to conduct Testing on them;

d) for each day during the following quarter, name and address of the place where the *Athlete* will be staying overnight (e.g. home, temporary accommodation, hotel, etc.);

e) for each day during the following quarter, the name and address of each location where the *Athlete* will train, work or conduct any other regular activity (e.g. school), as well as the usual time frames for such regular activities;

f) programme of sports events, including the name and address of each competition venue, where the *Athlete* plans to compete;

g) details of any *Athlete*'s impairment which may affect the procedure to be followed for conducting a Sample Collection Session.

3.4 In addition to the foregoing information, the *Athlete* shall also be required to state a specific 60 (sixty) minute time slot between 05:00 am and 11:00 pm for each day of the quarter during which he/she will be available and accessible at the specified location to undergo Testing. It is up to the *Athlete* to ensure accessibility to their selected 60 (sixty) minutes location with no advance warning to the *Athlete* (e.g., the location shall be easily accessible by Sample Collection Personnel, by indicating a street number or other item identifying the location must be available, the *Athlete*'s name must be shown on the door phone and/or notified to any concierge/reception desk services within the building/hotel, etc.). Under no circumstances shall the 60 (sixty) minute time slot limit the *Athlete*'s obligation to make himself/herself available for Testing at any time and at any location.

3.5 It is the *Athlete*'s explicit responsibility to ensure, including through updates entered in the *ADAMS* system as necessary such appropriate Whereabouts Information is supplied as to enable NADO Italia to locate him/her for Testing in any given day during the quarter, including, but not limited to, the 60 (sixty) minute time slot specified for that day in his/her Whereabouts Information.

3.6 More specifically, the *Athlete* shall provide sufficient information to enable the DCO to find the location, to gain access to the location, and to find the *Athlete* at the location with no advance notice to the *Athlete*. A failure to do so may be pursued as a Filing Failure and/or (if the circumstances so warrant) as evasion of *Sample* collection under *ADSC* Article 2.3, and/or *Tampering* or *Attempted Tampering* with *Doping Control* under *ADSC* Article 2.5. In any event, the *Anti-Doping Organization* shall consider *Target Testing* of the *Athlete* (e.g.: *declarations such as "running in the Black Forest" are insufficient and are likely to result in a Filing Failure. Similarly, specifying a location that the DCO cannot access is likely to result in a Filing Failure*).

3.7 If the *Athlete* is tested during the 60-minute time slot, the *Athlete* must remain with the DCO until the *Sample* collection has been completed, even if this takes longer than the 60-minute time slot. A failure to do so shall be pursued as an apparent violation of *ADSC* Article 2.3 (refusal or failure to submit to *Sample* collection).

3.8 If the *Athlete* is not available for *Testing* at the beginning of the 60-minute time slot, but becomes available for *Testing* later on in the 60-minute time slot, the DCO should collect the *Sample* and should not process the attempt as an unsuccessful attempt to test, but should report the details of the delay in availability of the *Athlete*. Any pattern of behavior of this type should be investigated as a possible anti-doping rule violation of evading *Sample* collection under *ADSC* Article 2.3 or *ADSC* Article 2.5. It may also prompt *Target Testing* of the *Athlete*. If an *Athlete* is not available for *Testing* during their specified 60-minute time slot at the location specified for that time slot for that day, they will be liable for a Missed Test even if they are located later that day and a *Sample* is successfully collected from them.

3.9 Once the DCO has arrived at the location specified for the 60-minute time slot, if the *Athlete* cannot be located immediately, then the DCO should remain at that location for whatever time is left of the 60-minute time slot and during that remaining time they should do what is reasonable in the circumstances to try to locate the *Athlete*.

3.10 Where a change in circumstances means that the information in a Whereabouts Filing is no longer accurate or complete, the *Athlete* shall file, through *ADAMS*, an update so that the information on file is again accurate and complete. The *Athlete* must always update their Whereabouts Filing to reflect any change in any day in the quarter in question in particular: (a) in the time or location of the 60-minute time slot; and/or (b) in the place where they are staying overnight. The *Athlete* shall file the update as soon as possible after they become aware of the change in circumstances, and in any event prior to the 60-minute time slot specified in their filing for the relevant day. Under specific circumstances, however, any updates made by the *Athlete* immediately before the start of the time slot may be considered as possible violations of the *ADSC*. A failure to do so may be pursued as a Filing Failure and/or (if the circumstances so warrant) as evasion of *Sample* collection under *ADSC* Article 2.3, and/or *Tampering* or Attempted *Tampering* with *Doping Control* under *ADSC* Article 2.5. In any event, NADO Italia shall consider *Target Testing* of the *Athlete*.

3.11 An *Athlete* included in an RTP may delegate the task of filing of all or part of the Whereabouts Information (and/or any update thereof) to a third party including, but not limited to, a coach, a Team (for Team Sports as under Article 4), a manager or National Federation, provided that the third party accepts such task.

However, each *Athlete* shall remain personally responsible for filing his/her accurate and complete Whereabouts Information even if such task is delegated and for being available for Testing at the times and locations specified in his/her Whereabouts. It shall not be a defence to an allegation of Filing Failure and/or Missed Test under *ADSC* Article 2.4 that the *Athlete* delegated responsibility for filing his/her Whereabouts Information to a third party and that third party failed to file correct/current/complete Whereabouts Information.

ARTICLE 4 WHEREABOUTS INFORMATION IN TEAM SPORTS

4.1 An *Athlete* engaging in a Team Sport or other sports discipline where competitions and/or training are held on a collective basis may delegate the task of filing Whereabouts Information to his/her own team, entrusting the latter's personnel and staff with such task.

4.2 Indeed, in Team Sports *Athlete*s are likely to carry out most of their activities (such as training, away matches, technical meetings) on a collective basis. As a result, most of the Whereabouts Information will be the same for all team *Athlete*s. In addition, in the event that an *Athlete* does not take part in a scheduled collective activity (e.g. due to injury), then he/she is likely to engage in other activities under the supervision of his/her team (e.g. therapy with the team physician).

4.3 An *Athlete* who engages in such sports may also delegate Whereabouts Filing requirements to his/her team not only with respect to the Team Activities as referred to above, but also with regard to periods that do not fall under such Activities, subject to his/her Team's consent. In this event, the *Athlete* shall be required to provide his/her team with such information, which will supplement the information supplied with respect to Team Activities.

4.4 Under the circumstances as described above, the *Athlete* shall however remain personally responsible for filing his/her accurate and complete Whereabouts Information and for being available for Testing at the times and locations specified in his/her Whereabouts. It shall not be a defence to an allegation of Filing Failure and/or Missed Test under *ADSC* Article 2.4 that the *Athlete* delegated responsibility for filing his/her Whereabouts Information to a third party and that third party failed to file correct/ current/complete Whereabouts Information.

4.5 Notwithstanding the foregoing, if an attempt to test an *Athlete* during the 60 (sixty) minute time slot as identified within a period included in Team Activities fails due to the team's Filing Failure, then the team shall be liable to undergo disciplinary proceedings with subsequent infliction of the financial sanctions as under *ADSC* Article 16.

TITLE II SAMPLE COLLECTION'S PROCEDURE

ARTICLE 5 NOTIFICATION OF *ATHLETE*

5.1 Notification starts when the Sample Collection Authority initiates the notification of the selected Athlete and ends when he/she arrives at the Doping Control Station or when the *Athlete*'s possible Failure to Comply has occurred.

The main activities are:

a) appointment of Sample Collection Personnel, sufficient to ensure No Advance Notice Testing and continuous observation of *Athletes* notified of their selection to provide a *Sample*;

b) locating the *Athlete* and confirming his/her identity;

c) informing the *Athlete* that he/she has been selected for *Testing* and of his/her rights and responsibilities;

d) continuously chaperoning the *Athlete* from the time of notification to the arrival at the designated Doping Control Station;

e) documenting the notification, or notification attempt.

5.2 Requirements prior to notification of *Athlete*s

5.2.1 No Advance Notice Testing shall be the method for *Sample* collection save in exceptional and justifiable circumstances. The *Athlete*s shall be the first Person notified that they have been selected for *Sample* collection, except where prior contact with a third party is required as specified in ISTI Article 5.3.7. In order to ensure that Testing is conducted on a No Advance Notice Testing basis, the Testing Authority (and the Sample Collection Authority, if different) shall ensure that *Athlete* selection decisions are only disclosed in advance of Testing to those who strictly need to know in order for such Testing to be conducted. Any notification to a third party shall be conducted in a secure and confidential manner so that there is no risk that the *Athlete* will receive any advance notice of their selection for *Sample* collection. For In-Competition Testing, such notification shall occur at the end of the Competition in which the Athlete is competing.

5.2.2 The Sample Collection Authority shall appoint and authorize Sample Collection Personnel who (i) have been trained for their assigned responsibilities, (ii) do not have a conflict of interest in relation to *Sample* collection procedures, and (iii) are not minors. Sample Collection Personnel shall have official documentation, provided by the Sample Collection Authority, evidencing their authority to collect a *Sample* from the *Athlete*, such as an authorization letter from NADO Italia. DCOs shall also be required to hold valid personal identification papers bearing a photograph (e.g. identity card, driver's license, passport) and the expiry date of the identification.

5.2.3 The *Athlete* selected for Testing shall be identified through his/her identity papers, federation membership card if bearing a photograph, or any piece of photo identification. If a photo identification is not available, the DCO/Chaperone will write on *Doping Control* Form 'No Document' in the 'Type of Identification' box. The DCO will then document how the *Athlete* was identified in the 'Comments' box of the DCF and the DCO Report Form. The DCO/Chaperone shall be required to document and record, using the Supplementary Report, any (i) circumstances where the *Athlete*'s identity is confirmed using other methods, or (ii) failure to confirm the *Athlete*'s identity. The Sample Collection Personnel shall document *Athlete* notification attempt(s) and outcome(s). The DCO and/or Chaperone shall establish the location of the selected *Athlete* and plan the approach and timing of notification, taking into consideration the specific circumstances of the sport/competition/training session.

5.2.4 Notification of testing shall be served personally on the *Athlete* selected for Testing, unless a third party is required to be notified prior to notification of the *Athlete* in the following situations:

a) where required by an *Athlete*'s impairment (as provided for in Annex A - Modifications for *Athlete*s with Impairments);
b) where the *Athlete* is a Minor (as provided for in Annex B – Modifications for *Athlete*s who are Minors);
c) where an interpreter is required and available for the notification;
d) where required to assist Sample Collection Personnel to identify the *Athlete*(s) to be tested and to notify such *Athlete*(s) that they are required to provide a *Sample*.

ARTICLE 6 REQUIREMENTS FOR NOTIFICATION OF *ATHLETE*S

6.1 When initial contact is made, the Sample Collection Personnel shall ensure that the *Athlete* and/or a third party is informed:

a) that the *Athlete* is required to undergo a *Sample* collection;
b) of the authority under which the *Sample* collection is to be conducted;
c) of the type and method of *Sample* collection and any conditions that need to be adhered or the purposes of *Sample* collection;
d) of the *Athlete*'s rights, including the right to:
   i. have a representative and, if necessary, an interpreter accompany him/her;
   ii. ask for additional information about the *Sample* collection process;
   iii. request a delay in reporting to the Doping Control Station for valid reasons;
   iv. request modifications as provided for in Annex A – Modifications for *Athlete*s with Impairments;
e) of the *Athlete*'s responsibilities, including the requirement to:
   i. remain within direct observation of the Sample Collection Personnel at all times from the time of notification until the completion of the *Sample* collection procedure;
   ii. produce identification in accordance with Article 5.2.3;
   iii. comply with *Sample* collection procedures (and the *Athlete* should be informed of the possible consequences of Failure to Comply);
   iv. report immediately for *Sample* collection, unless there are valid reasons for a delay, as determined in accordance with Article 6.3 here below;
f) of the location of the Doping Control Station;
g) that should the *Athlete* choose to consume food or fluids prior to providing a *Sample*, he/she does so at his/her own risk, while advising him/her that he/she should not hydrate excessively, having in mind the requirement to provide a *Sample* with a Suitable Specific Gravity for Analysis;
h) that the urine *Sample* provided by the *Athlete* to the Sample Collection Personnel should be the first urine passed by the *Athlete* subsequent to notification.

6.2 After contact is made with the *Athlete*, the Sample Collection Personnel shall:

a) keep the *Athlete* under observation at all times until the end of the *Sample* Collection Session;
b) identify themselves to the *Athlete* using the documentation referred to in Article 5.2.2;

c) confirm the *Athlete*'s identity as per the criteria established in Article 5.2.3. Any cases where the *Athlete*'s identity cannot be confirmed it must be documented and reported to NADO Italia. NADO Italia shall decide whether it is appropriate to follow up in accordance with Annex A – Review of a Possible Failure to Comply of the *Results Management Procedure*.

The Sample Collection Personnel shall then have the *Athlete* sign an appropriate form to acknowledge and accept the notification. If the *Athlete* refuses to sign that he/she has been notified, or evades the notification, the Sample Collection Personnel shall, if possible, inform the *Athlete* of the Consequences of refusing or failing to comply, and the Chaperone (if not the DCO) shall immediately report all relevant facts to the DCO, documenting such circumstance and informing NADO Italia. NADO Italia follows the steps prescribed in Annex A – Review of a Possible Failure to Comply of the *Results Management Procedure*.
The DCO shall at any rate be required to carry on the *Sample* collection procedure.

6.3 The Sample Collection Personnel may at their discretion consider any reasonable third party request or any request by the *Athlete* for permission to delay reporting to the Doping Control Station following acknowledgment and acceptance of notification, and/or to leave the Doping Control Station temporarily after arrival, and may grant such permission if the *Athlete* can be continuously chaperoned and kept under direct observation during the delay. For example, delayed reporting to or temporary departure from the Doping Control Station may be permitted for the following activities:

- For In-Competition Testing:

a) Participation in a presentation ceremony;

b) Fulfilment of media commitments;

c) Competing in further competitions;

d) Performing a warm down;

e) Obtaining necessary medical treatment;

f) Locating a representative and/or interpreter;

g) Obtaining photo identification; or

h) Any other reasonable circumstances, as determined by DCO, taking into account any instructions of NADO Italia.

- For Out-of-Competition Testing:

a) Locating a representative;

b) Completing a training session;

c) Receiving necessary medical treatment;

d) Obtaining photo identification; or

e) Any other reasonable circumstances, as determined by DCO, considering any instructions of NADO Italia.

6.4 The Sample Collection Personnel shall reject a request for delay in reporting to the Doping Control Station if it is not possible for the *Athlete* to be continuously observed during such delay.
The Sample Collection Personnel shall use the Supplementary Report to document any reasons for the *Athlete*'s delay in reporting to the Doping Control Station and/or reasons for leaving the Doping Control Station that may require further investigation by NADO Italia.

6.5 If the *Athlete* delays reporting to the Doping Control Station other than in accordance with Article 6.3 and/or any failure of the *Athlete* to remain under constant observation during chaperoning but the *Athlete* arrives at the Doping Control Station prior to the DCO's departure from the *Sample* collection location, the DCO shall report a possible Failure to Comply. If at all possible, the DCO shall proceed with collecting a *Sample* from the *Athlete*. NADO Italia shall investigate a possible Failure to Comply in accordance with Annex A – Review of a Possible Failure to Comply of the *Results Management Procedure*.

6.6 If Sample Collection Personnel observe any other matter with potential to compromise the collection of the *Sample*, the circumstances shall be reported to and documented by the DCO. If deemed appropriate by the DCO, the DCO shall consider if it is appropriate to collect an additional *Sample* from the *Athlete*. NADO Italia shall investigate a possible Failure to Comply in accordance with Annex A – Review of a Possible Failure to Comply of the *Results Management Procedure*.

ARTICLE 7 DCO AND BCO's DUTIES

As pursuant to the provisions laid down in the ISTI, Annex G and in the WADA Guidelines, the DCO/BCO are Sample Collection Personnel responsible for *Sample* collection-related services.

The DCO shall be responsible for:

a) Organizing and training any additional Sample Collection Personnel;

b) Contacting sports representatives, if necessary;

c) Organizing equipment, including all forms and documents as necessary;

d) Assessing and arranging facilities;

e) Arranging and performing notification and chaperoning of *Athlete*s;

f) Ensuring that the *Athlete* is informed about his/her rights and responsibilities;

g) Witnessing DCO entitlement to have a representative observe the witnessing DCO when the Minor Athlete is passing a urine Sample;

h) Explaining the process of Urine *Sample* or Blood *Sample* collection to the *Athlete*s and *Athlete*s' representatives, as necessary;

i) Overseeing *Sample* collection, including witnessing Sample provision;

j) Coordinating Blood *Sample* collection, as necessary;

k) Completing and verifying the relevant forms and documentation;

l) Initiating and supervising the Chain of Custody of the testing phase, including

organizing a delivery service, if necessary, ensuring that the waybill number is duly recorded if *Sample* transportation is arranged through a courier service;

m) Dealing with the collection and disposal of waste resulting from *Sample* collection procedures.

ARTICLE 8 CHAPERONE'S DUTIES

As pursuant to the provisions laid down in the *WADA* Guidelines, a Chaperone shall be responsible for:

a) Assisting the DCO in the conduct of anti-doping controls while strictly following his/her instructions;

b) Informing the *Athlete* about his/her own identity by producing the official card and/or document vesting him/her with power of Chaperone;

c) Personally informing the *Athlete* of the need for him/her to undergo Testing and his/her rights and duties, according to the DCO' instructions;

d) Accompanying the *Athlete* while keeping direct visual contact from the time of notification to the *Athlete*'s arrival at the Doping Control Station and thereafter, if so required by the DCO.

ARTICLE 9 DUTIES OF ANTI-DOPING DETECTIVE INSPECTORS (ADDIs)

Pursuant to the Memorandum of Understanding signed on 22 July 2022 between NADO Italia and the Carabinieri Department for Health Protection (i.e., the Italian anti-adulteration unit locally known as "NAS" or "CCTS"), NAS personnel accredited by NADO Italia as Anti-Doping Detective Inspectors ("ADDIs") may take part to the anti-doping activities, in conjunction with FMSI's Doping Control Officers/Blood Control Officers.

During Testing as well as In-Competition Sample Collection Sessions, the ADDIs, if appointed, shall perform the following tasks in particular:

a) To the extent as lying within their province and without prejudice to the duties and responsibilities of the DCO/BCO and Chaperones, they supervise the conduct of all of anti-doping phases in compliance with the ADSRs, such as:

- Notification of Testing;
- Sample Collection Session;
- Documenting testing operations;

b) When attending anti-doping procedures, they shall be required to show the card issued by NADO Italia and, if expressly requested by the *Athlete* or his/her representative, their personal identification card issued by the Carabinieri Corps;

c) In conjunction with the DCO and Chaperone, they help identify *Athlete*s who are unable to produce identity papers or a Federation membership card bearing a photo;

d) They shall request the DCO to include the following in the anti-doping report:

- Any requests made by the *Athlete*/third parties to (i) interrupt the *Sample* collection phase due to kits that the *Athlete* claims to be non-compliant, or (ii) delay reporting to the Doping Control Station after notification has been received and accepted, or (iii) temporarily leave the Doping Control Station after arrival.
- *Athlete*'s late arrival or early departure;
- Any doubts arisen regarding the origin and genuineness of the *Sample* and the *Athlete*'s request to produce another *Sample*;
- Any other matter that may compromise the legitimacy of the analyses or procedure compliance;
- Any refusal by the *Athlete* to produce an additional *Sample* or sign the notification form.

e) They shall sign the anti-doping control report together with all the other individuals attending the proceedings.

During Out-of-Competition Testing as well as Sample Collection Sessions, the ADDIs, if appointed, shall perform the following tasks:

a) Help find the exact location of the *Athlete*(s) selected for Testing;

b) To the extent as lying within their province and without prejudice to the duties and responsibilities of the DCO/BCO and Chaperones, they supervise the conduct of all of anti-doping phases in compliance with the ADSRs, such as:

- Notification of Testing;
- Sample Collection Session;
- Documenting testing operations;

c) When attending anti-doping procedures, they shall be required to show the card issued by NADO Italia and, if expressly requested by the *Athlete* or his/her representative, their personal identification card issued by the Carabinieri Corps;

d) In conjunction with the DCO, they help identify *Athlete*s who are unable to produce identity papers or a Federation membership card bearing a photo;

e) They shall request the DCO to include the following in the anti-doping report:

- Any requests made by the *Athlete*/third parties to (i) interrupt the *Sample* collection phase due to kits that the *Athlete* claims to be non-compliant, or (ii) delay reporting to the Doping Control Station after notification has been received and accepted, or (iii) temporarily leave the Doping Control Station

after arrival.

- *Athlete*'s late arrival or early departure;
- Any doubts arisen regarding the origin and genuineness of the *Sample* and the *Athlete*'s request to produce another *Sample*;
- Any other matter that may compromise the legitimacy of the analyses or procedure compliance;
- Any refusal by the *Athlete* to produce an additional *Sample* or sign the notification form.

f) They help identify the site where Testing is to be conducted;

g) They shall sign the anti-doping control report together with all the other individuals attending the proceedings.

TITLE III SAMPLE COLLECTION SESSION

ARTICLE 10 PREPARING FOR THE SAMPLE COLLECTION SESSION

10.1 For the purpose holding a Sample Collection Session, the following requirements need to be fulfilled beforehand:

a) establishing an information collection system;
b) establishing criteria for who may be present during a Sample Collection Session;
c) ensuring that the Doping Control Station meets the minimum criteria prescribed in Article 7.3;
d) ensuring that the Sample Collection Equipment meets the minimum criteria prescribed in ISTI Article 6.3.4.

10.2 NADO Italia and the Sample Collection Authority shall establish a system for obtaining all the information necessary to ensure that the Sample Collection Session can be conducted effectively, including identifying specific requirements to meet the needs of *Athlete*s with impairments (as provided in Annex A - Modifications for *Athlete*s with Impairments) as well as the needs of *Athlete*s who are *Minors* (as provided in Annex B - Modifications for *Athlete*s who are *Minors*), consistent with applicable privacy provisions.

10.3 The Sample Collection Authority shall be required to use a Doping Control Station which, at a minimum, ensures the *Athlete*'s privacy and confidentiality and is used solely as a Doping Control Station throughout the Session. Moreover, according to the WADA Guidelines applicable to In- Competition Testing, where possible, the Doping Control Station shall meet the following criteria:

a) be accessible only to authorized personnel;
b) be secure enough to store Sample Collection Equipment;
c) be comprised of a waiting area with chairs and a separate area with a table and chairs for

completion of paperwork. There should be adjacent toilet facilities large enough to allow *Sample* provision to be observed.

d) include facilities to allow the *Athlete* to wash his/her hands;

e) be large enough to accommodate the *Athlete*s as well as authorized personnel;

f) be suitably located in relation to the field of play or other location where *Athlete*s will be notified.

With regard to Out-of-Competition Testing, when identifying the most suitable location the DCO/BCO shall take into account the demands and needs of the *Athlete* and/ third parties concerned with respect to privacy and dignity rights. However, no information concerning the *Athlete*'s private life or unrelated third parties (e.g. family members) which is deemed as unnecessary, irrelevant or exceeding doping control purposes shall be collected.

Any non-compliance with the aforesaid requirements shall be documented by the DCO/BCO in the Supplementary Report form.

The Sample Collection Authority shall only use Sample Collection Equipment systems for urine and blood *Samples* which, at a minimum, complies with the requirements set out in ISTI Article 6.3.4.

10.4 In addition to the Sample Collection Personnel, the following people may be authorized by NADO Italia, to be present during the Sample Collection Session:

a) representative and/or interpreter, if requested by the *Athlete*, except when the *Athlete* is passing a urine *Sample*;

b) a Minor *Athlete*'s entitlement (as provided for in Annex B – Modifications for *Athlete*s who are Minors), and the witnessing DCO's entitlement to have a representative observe the witnessing DCO when the Minor *Athlete* is passing a urine *Sample*, but without the representative directly observing the passing of the *Sample* unless requested to do so by the Minor *Athlete*;

c) a representative who accompanies an *Athlete* with impairment, if requested by the latter, pursuant to Annex A – Modifications for *Athlete*s with Impairments;

d) an Independent Observer, if sent by WADA under the *Independent Observer Programme*, or WADA auditor, where applicable;

e) an authorized Person who is involved in the training of Sample Collection Personnel or auditing the Sample Collection Authority;

f) a NADO Italia Observer if officially appointed for the event, including Anti-Doping Detective Inspectors ("ADDIs") as referred to in *ADSC* Article 6.7.

The WADA observer/auditor and/or authorized Person shall not directly observe the passing of a urine *Sample*.

ARTICLE 11 CONDUCTING THE SAMPLE COLLECTION SESSION

11.1 The Sample Collection Session starts with defining the overall responsibility for the conduct of the Sample Collection Session and ends once the *Sample* has been collected and secured and the Sample Collection Session documentation is complete.

11.2 The main activities are:

a) preparing for collecting the *Sample*;

b) collecting and taking all steps to secure the *Sample*;

c) documenting the *Sample* collection.

11.3 The Sample Collection Authority shall be responsible for the overall conduct of the Sample Collection Session, with specific responsibilities being either delegated to or lying with the DCO/BCO.

11.4 The DCO shall ensure that the *Athlete* has been informed of his/her rights and responsibilities.

11.5 The DCO shall advise the *Athlete* not to hydrate excessively, having in mind the requirement to provide a *Sample* with a Suitable Specific Gravity for Analysis.

11.6 NADO Italia prohibits the provision of alcohol or its consumption within the Doping Control Station.

11.7 The *Athlete* shall only leave the Doping Control Station under continuous observation by the DCO or Chaperone and with the approval of the DCO. The DCO shall consider any reasonable request by the *Athlete* to leave the Doping Control Station, as specified in Article 6.3, until the *Athlete* is able to provide a *Sample*.

11.8 If the DCO gives approval for the *Athlete* to leave the Doping Control Station, the DCO shall agree with the *Athlete* on the following conditions of leave:

a) the purpose of the *Athlete* leaving the Doping Control Station;

b) establish and agree with the *Athlete* the time of return (or return upon completion of an agreed activity).

c) ensure that the *Athlete* remains under continuous observation throughout;

d) restrict the *Athlete* from passing urine until he/she returns to the Doping Control Station.

e) the DCO shall be required to document the actual time of the *Athlete*'s departure and return.

11.9 The DCO shall collect the *Sample* from the *Athlete* according to the following protocol(s) for the specified type of *Sample* collection:

a) Annex C: Collection of Urine *Samples*;

b) Annex D: Collection of Blood *Samples*;

c) Annex I: Collection, Storage and Transportation of Blood *Athlete* Biological Passport *Samples*;

d) Annex J: Collection, Storage and Transport of Dried Blood Spot *Samples*

11.10 Any behaviour by the *Athlete* and/or Persons associated with the *Athlete* or anomalies with potential to compromise the *Sample* collection shall be recorded in detail by the DCO using the Supplementary Report form. If appropriate, NADO Italia shall institute the procedures under Annex A – Review of a possible Failure to Comply, *Results Managements Procedure*.

11.11 If there are doubts as to the origin or authenticity of the *Sample*, the *Athlete* shall be asked to provide an additional *Sample*. If the *Athlete* refuses to provide an additional *Sample*, the DCO shall document in detail the circumstances around the refusal using the Supplementary Report form, and NADO Italia shall institute the procedures under Annex A – Review of a possible Failure to Comply, *Results Managements Procedure*.

11.12 The DCO shall provide the *Athlete* with the opportunity to document any concerns he/she may have about how the Sample Collection Session was conducted.

11.13 In conducting the Sample Collection Session, the following information shall be recorded in the relevant report:

a) date, time of notification, name and signature of notifying DCO/Chaperone;
b) arrival time of the *Athlete* at the Doping Control Station and any temporary departures and returns;
c) date and time of sealing of each *Sample* collected and date and time of completion of entire *Sample* collection process (i.e., the time when the *Athlete* signs the declaration at the bottom of the Doping Control form);
d) the name of the *Athlete*;
e) the date of birth of the *Athlete*;
f) the gender of the *Athlete*;
g) means by which the *Athlete*'s identity is validated (e.g., passport, driver's license or *Athlete* accreditation) including by a third party (who is so identified)
h) the *Athlete*'s home address, email address and telephone number;
i) the *Athlete*'s sport and discipline (in accordance with the TDSSA);
j) the name of the *Athlete*'s coach and doctor (if applicable);
k) the *Sample* code number and reference to the equipment manufacturer; and, where the *Sample* collected is dried blood spot, detailed information on the model of the dried blood spot *Sample* Collection Equipment (e.g., catalogue number) if the equipment manufacturer commercializes several dried blood spot *Sample* collection kits;
l) the type of the *Sample* (urine, blood, dried blood spot, etc.);
m) the type of Testing (In-Competition or Out-of-Competition);
n) the name and signature of the witnessing DCO;
o) the name and signature of the BCO (where applicable);
p) partial *Sample* information, as per Article E.4.4, Annex E;
q) required Laboratory information on the *Sample* (i.e., for a urine *Sample*, its volume and specific gravity measurement), as per ISTI Article 8.3.3;

r) medications and supplements taken within the previous seven (7) days and (where the *Sample* collected is a blood *Sample*) blood transfusions within the previous three (3) months, as declared by the *Athlete*;
s) for a blood *Athlete Biological Passport Sample*, the DCO/BCO shall record the information as outlined in Annex I - Collection, Storage and Transport of Blood *Athlete* Biological Passport *Samples*;
t) any irregularities in procedures, for example, if advance notice was provided;
u) *Athlete* comments or concerns regarding the conduct of the Sample Collection Session, as declared by the *Athlete*;
v) *Athlete* acknowledgment of the Processing of *Sample* collection data and description of such Processing in accordance with the International Standard for the Protection of Privacy and Personal Information, with the GDPR, EU 2016/679 and pursuant to Legislative Decree n. 196/2003 as amended by Legislative Decree n. 101/2018;
w) *Athlete* consent or otherwise for the use of the *Sample*(*s*) for research purposes;
x) the name and signature of the *Athlete*'s representative (if applicable);
y) the name and signature of the *Athlete*;
z) the name and signature of the DCO;
aa) the name of the Testing Authority;
bb) the name of the Sample Collection Authority;
cc) the name of the Results Management Authority; and
dd) the name of the Doping Control Coordinator (if applicable).

11.14 At the conclusion of the Sample Collection Session, the *Athlete* and DCO shall sign appropriate documentation to indicate their satisfaction that the documentation accurately reflects the details of the *Athlete*'s Sample Collection Session, including any concerns expressed by the *Athlete*. The *Athlete*'s representative, if present and who witnessed the proceedings, should sign the documentation. Other persons present who had a formal role during the *Athlete*'s Sample Collection Session may sign the documentation as a witness of the proceedings.

11.15 The DCO shall provide the *Athlete* with a copy of the records of the Sample Collection Session that have been signed by the *Athlete*.

11.16 The *Doping Control Form*, duly completed and signed in all of its sections by the DCO, shall be prepared in 3 copies (NADO Italia, *Athlete* and WADA-accredited laboratory) and delivered as follows:

a) NADO Italia: The DCO shall arrange for the reports of all the *Athlete*s to be placed in an envelope bearing the details of the NSF/ASD/SPE concerned (or ADO/Organization concerned), event, venue and date. The envelope shall be promptly sent to NADO Italia. The *Athlete*'s notification, the Supplementary Report (if any) and other documentation shall be placed solely in the parcel to be delivered to NADO Italia.

b) *Athlete*: Upon completion of the Sample Collection Session, the DCO shall hand over to the *Athlete* his/her copy of the session report.

c) Laboratory: The copy(ies) intended for the WADA-accredited laboratory shall not contain any information identifying the *Athlete* and shall be placed by the DCO in a carrying case

containing the collected *Samples*, while the Chain of Custody shall be kept out of the case in order that it may be updated during the different stages.

TITLE IV SECURITY, POST-TEST ADMINISTRATION PROCEDURE, TRANSPORT AND OWNERSHIP OF SAMPLES

ARTICLE 12 REQUIREMENTS

12.1 Post-Test administration begins when the *Athlete* has left the Doping Control Station after providing his/her *Sample*(*s*), and ends with preparation of all of the collected *Samples* and *Sample* collection documentation for transport.

12.2 The Sample Collection Authority shall, through the DCO, ensure that all sealed *Samples* are stored in a manner that protects their integrity, identity and security prior to transport from the Doping Control Station. In the event that the Samples are stored, the location where *Samples* are stored, who has custody of the *Samples* and/or who is permitted access to the *Samples* shall also be documented.

12.3 The Sample Collection Authority shall develop a system for recording the Chain of Custody of the *Samples* and *Sample* collection documentation to ensure that the documentation for each *Sample* is completed and securely handled. This shall include confirming that both the *Samples* and *Sample* collection documentation have arrived at their intended destinations. The Laboratory shall report any irregularities to NADO Italia on the condition of *Samples* upon arrival in line with the *International Standard for Laboratories* (ISL).

12.4 Insofar as necessary, NADO Italia, through the DCO, shall ensure that instructions for the type of analysis to be conducted are provided to the WADA-accredited laboratory or other WADA-approved laboratory. In addition, NADO Italia, shall, through the DCO, provide the information as under ISTI Article 7.4.5, paragraphs c), f), i), k), l), m), q), r), w), aa), bb), cc) for result reporting and statistical purposes. To this end, the copy of the form designed for the laboratory shall be used.

ARTICLE 13 TRANSPORT OF SAMPLES AND DOCUMENTATION

13.1 Transport starts when the sealed *Samples* and related Sample Collection Session documentation leave the Doping Control Station and ends with the confirmed receipt of the *Samples* and related documentation at their intended destinations.

13.2 The Sample Collection Authority shall authorize a transport system that ensures *Samples* and documentation are transported in a manner that protects their integrity, identity and security.

13.3 *Samples* shall always be transported to the Laboratory that will be analyzing the *Samples* using the Sample Collection Authority's authorized transport method, as soon as possible after the completion of the Sample Collection Session. *Samples* shall be transported in a manner which minimizes the potential for Sample degradation due to factors such as time delays and extreme

temperature variations.

13.4 The documentation identifying the *Athlete* shall not be attached to the *Samples* or documentation sent to the laboratory.

13.5 If the *Samples*, complete with the relevant documentation or Sample Collection Session report, are not acknowledged to have been received at their respective intended destinations, or if a Sample's integrity, identity or security may have been compromised during transport, then the Sample Collection Authority shall check the Chain of Custody, and NADO Italia shall consider whether the *Samples* should be voided.

13.6 Documentation related to a Sample Collection Session and/or an anti-doping rule violation shall be stored for the period and other requirements specified in the International Standard for the Protection of Privacy and Personal Information, and according to GDPR, EU 2016/679 and pursuant to Legislative Decree no. 196/2003 as amended by Legislative Decree no. 101/2018.

ARTICLE 14 OWNERSHIP OF SAMPLES

14.1 *Samples* collected from an *Athlete* are owned by NADO Italia for the Sample Collection Session in question.

14.2 NADO Italia, upon request, may transfer such ownership to the Anti-Doping Organization responsible for *Results Management*, if different from NADO Italia or to another Anti-Doping Organization upon request.

14.3 WADA may assume Testing Authority in certain circumstances in accordance with the Code and the ISL.

14.4 Where NADO Italia is not the Passport Custodian, but initiated and directed the Sample collection, it maintains the responsibility for additional Analytical Testing of the Sample. This includes the performance of further Confirmation Procedure(s) upon requests generated automatically by the Adaptive Model of the *Athlete* Biological Passport in *ADAMS* (e.g., GC/C/IRMS triggered by elevated T/E) or a request by the APMU (e.g., GC/C/IRMS requested due to abnormal secondary Markers of the urinary "longitudinal steroid profile" or erythropoietin receptor agonists (ERAs) analysis tests due to suspicious hematological Marker values).

TITLE V STANDARDS FOR INTELLIGENCE GATHERING AND INVESTIGATION

ARTICLE 15 GATHERING, ASSESSMENT AND USE OF INTELLIGENCE

15.1 NADO Italia ensures it's able to obtain, assess and process anti-doping intelligence from all available sources, to help deter and detect doping, to inform the development of an effective, intelligent and proportionate Test Distribution Plan, to plan Target Testing, and to conduct investigations as required by *Code* Article 5.7. The objective of this Article is to establish

standards for the efficient and effective gathering, assessment and processing of such intelligence for these purposes.

15.2 NADO Italia does everything in its power to ensure that it is able to capture or receive anti-doping intelligence from all available sources, including, but not limited to, *Athletes* and *Athlete Support Personnel* (including Substantial Assistance provided pursuant to *Code* Article 10.7.1) and members of the public (e.g., by means of a confidential telephone hotline), Sample Collection Personnel (whether via mission reports, incident reports, or otherwise), Laboratories, pharmaceutical companies, other Anti-Doping Organizations, WADA, National Federations, law enforcement, other regulatory and disciplinary bodies, and the media (in all its forms).

15. 3 NADO Italia adopts a policy to ensure that anti-doping intelligence captured or received is handled securely and confidentially, that sources of intelligence are protected, that the risk of leaks or inadvertent disclosure is properly addressed, and that intelligence shared with them by law enforcement, other relevant authorities and/or other third parties, is processed, used and disclosed only for legitimate anti-doping purposes.

15.4 NADO Italia ensures that it is able to assess all anti-doping intelligence upon receipt for relevance, reliability and accuracy, taking into account the nature of the source and the circumstances in which the intelligence has been captured or received.

15.5 All anti-doping intelligence captured or received by NADO Italia should be collated and analyzed to establish patterns, trends and relationships that may assist the Anti-Doping Organization in developing an effective anti-doping strategy and/or in determining (where the intelligence relates to a particular case) whether there is reasonable cause to suspect that an anti-doping rule violation may have been committed, such that further investigation is warranted in accordance with ISTI Article 12 and the International Standard for Results Management.

15.6 Anti-doping intelligence shall be used to assist for the following purposes (without limitation): developing, reviewing and revising the Test Distribution Plan and/or determining when to conduct Target Testing, in each case in accordance with ISTI Article 4 and/or to create targeted intelligence files to be referred for investigation in accordance with ISTI Article 12.

15.7 NADO Italia should also develop and implement policies and procedures for the sharing of intelligence (where appropriate, and subject to applicable law) with other Anti-Doping Organizations (e.g., if the intelligence relates to *Athletes* or other Persons under their authority) and/or law enforcement and/or other relevant regulatory or disciplinary authorities (e.g., if the intelligence suggests the possible commission of a crime or regulatory offence or breach of other rules of conduct).

15.8 NADO Italia should develop and implement policies and procedures to facilitate and encourage confidential sources as outlined within WADA's Confidential Source Policy available on WADA's website.

ARTICLE 16 INVESTIGATIONS

16.1 The objective of ISTI Article 12 is to establish standards for the efficient and effective conduct of investigations that *Anti-Doping Organizations* must implement under the Code, including but not limited to:
a) The investigation of *Atypical Findings*, *Atypical Passport Findings* and *Adverse Passport Findings*, in accordance with the International Standard for Results Management;
b) The investigation of any other analytical or non-analytical information and/or intelligence where there is reasonable cause to suspect that an anti-doping rule violation may have been committed, in accordance with the International Standard for Results Management;
c) The investigation of the circumstances surrounding and/or arising from an Adverse Analytical Finding to gain further intelligence on other Persons or methods involved in doping (e.g., interviewing the relevant *Athlete*); and
d) Where an anti-doping rule violation by an *Athlete* is established, the investigation into whether *Athlete* Support Personnel or other Persons may have been involved in that violation, in accordance with Code Article 20.

16.2 In each case, the purpose of the investigation is to achieve one of the following either:
a) to rule out the possible violation/involvement in a violation;
b) to develop evidence that supports the initiation of an anti-doping rule violation proceeding in accordance with *Code* Article 8; or
c) to provide evidence of a breach of the *Code* or applicable International Standard.

16.3 NADO Italia shall ensure it is able to investigate confidentially and effectively any analytical or non-analytical information or intelligence that indicates there is reasonable cause to suspect that an anti-doping rule violation may have been committed, in accordance with the International Standard for Results Management.

16.4 NADO Italia shall gather and record all relevant information and documentation as soon as possible, in order to develop that information and documentation into admissible and reliable evidence in relation to the possible antidoping rule violation, and/or to identify further lines of enquiry that may lead to the discovery of such evidence. NADO Italia shall ensure that investigations are conducted fairly, objectively and impartially at all times. The conduct of investigations, the evaluation of information and evidence identified in the course of that investigation, and the outcome of the investigation, shall be fully documented.

16.5 NADO Italia should make use of all investigative resources reasonably available to it to conduct its investigation. This may include obtaining information and assistance from law enforcement and other relevant authorities, including other regulators. However, NADO Italia should also make full use of all investigative resources at its own disposal, including the *Athlete Biological Passport program*, investigative powers conferred under applicable rules (e.g., the power to demand the production of relevant documents and information, and the power to interview both potential witnesses and the *Athlete* or other Person who is the subject of the investigation), and the power to suspend a period of Ineligibility imposed on an Athlete or other Person in return for the provision of Substantial Assistance in accordance with *Code* Article 10.7.1.

16.6 *Athletes* and *Athlete Support Personnel* are required under *Code* Article 21 to cooperate with

investigations conducted by Anti-Doping Organizations. If they fail to do so, disciplinary action should be taken against them under applicable rules. If their conduct amounts to subversion of the investigation process (e.g., by providing false, misleading or incomplete information, and/or by destroying potential evidence), NADO Italia should bring proceedings against them for violation of *Code* Article 2.5 (Tampering or Attempted Tampering).

16.7 NADO Italia shall come to a decision efficiently and without undue delay as to whether proceedings should be brought against the *Athlete* or other Person asserting commission of an anti-doping rule violation. As set out in *Code* Article 13.3, if an Anti-Doping Organization fails to make such decision within a reasonable deadline set by WADA, WADA may elect to appeal directly to CAS as if the Anti-Doping Organization had rendered a decision finding that no anti-doping rule violation has been committed. As noted in the comment to Code Article 13.3, however, before taking such action WADA will consult with the Anti-Doping Organization and give it an opportunity to explain why it has not yet rendered a decision

16.8 Where NADO Italia concludes based on the results of its investigation that proceedings should be brought against the *Athlete* or other Person asserting commission of an anti-doping rule violation, it shall give notice of that decision in the manner set out in the International Standard for Results Management and shall bring forward the proceedings against the *Athlete* or other Person in question in accordance with *Code* Article 8.

16.9 Where NADO Italia concludes, based on the results of its investigation, that proceedings should not be brought forward against the *Athlete* or other Person asserting commission of an anti-doping rule violation:

16.9.1 It shall notify *WADA* and the *Athlete's* or other Person's International Federation and *National Anti-Doping Organization* in writing of that decision, with reasons, in accordance with *Code* Article 14.1.4.

16.9.2 It shall provide such other information about the investigation as is reasonably required by *WADA* and/or the International Federation and/or National Anti-Doping Organization in order to determine whether to appeal against that decision.

16.9.3 In any event, it shall consider whether any of the intelligence obtained and/or lessons learned during the investigation should be used to inform the development of its Test Distribution Plan and/or to plan Target Testing, and/or should be shared with any other body in accordance with ISTI Article 11.4.2.

ANNEX A – MODIFICATIONS FOR *ATHLETE*S WITH IMPAIRMENTS

A.1. Objective

To ensure, where possible, that the particular needs of *Athlete*s with impairments are considered in relation to the provision of a Sample without compromising the integrity of the Sample Collection Session.

A.2. Scope

Determining whether modifications are necessary starts with identification of situations where Sample collection involves *Athlete*s with impairments and ends with modifications to Sample collection procedures and equipment where necessary and where possible.

A.3. Responsibility

A.3.1 NADO Italia or the Sample Collection Authority (as applicable) has responsibility for ensuring, when possible, that the DCO has any information and Sample Collection Equipment necessary to conduct a Sample Collection Session with an *Athlete* with an impairment, including details of such impairment that may affect the procedure to be followed in conducting a Sample Collection Session.

A.3.2 The DCO has responsibility for Sample collection.

A.4. Requirements

A.4.1 All aspects of notification and Sample collection for *Athlete*s with impairments shall be carried out in accordance with the standard notification and Sample collection procedures unless modifications are necessary due to the *Athlete*'s impairment. NADO Italia in the case of an Athlete with an intellectual impairment, shall decide whether to obtain consent to Testing from their representative and inform the Sample Collection Authority and Sample Collection Personnel.

A.4.2 In planning or arranging Sample collection, the Sample Collection Authority and DCO shall consider whether there will be any Sample collection for *Athlete*s with impairments that may require modifications to the standard procedures for notification or Sample collection, including Sample Collection Equipment and Doping Control Station.

A.4.3 The Sample Collection Authority and DCO shall have the authority to make modifications as the situation requires when possible and as long as such modifications will not compromise the integrity, identity and security of the *Sample*. The DCO shall consult the *Athlete* in order to determine what modifications may be necessary for the *Athlete*'s impairment. All such modifications shall be documented.

A.4.4 An *Athlete* with an intellectual, physical or sensorial impairment may be assisted by the *Athlete*'s representative or Sample Collection Personnel during the Sample Collection Session where authorized by the *Athlete* and agreed to by the DCO.

A.4.5 The DCO may decide that alternative Sample Collection Equipment or an alternative Doping Control Station will be used when required to enable the *Athlete* to provide the Sample, as long as the Sample's integrity, identity and security and will not be affected.

A.4.6 *Athlete*s who are using urine collection or drainage systems are required to eliminate existing urine from such systems before providing a urine Sample for analysis. Where possible, the existing urine collection or drainage system should be replaced with a new, unused catheter or drainage system prior to collection of the Sample.

A.4.7 Should an *Athlete* require any additional equipment in order to be able to provide a *Sample*, including but not limited to catheters and drainage systems, it is the sole responsibility of the *Athlete* to have the necessary equipment available for this purpose and understand how to use it.

A.4.8 For *Athlete*s with vision or intellectual impairments, the DCO and/or *Athlete* may determine if they shall have a representative present during the Sample Collection Session. During the Sample Collection Session, a representative of the *Athlete* and/or a representative of the DCO may observe the witnessing DCO while the *Athlete* is passing the urine Sample. This representative or these representatives may not directly observe the passing of the urine Sample, unless requested to do so by the *Athlete*.

A.4.9 The DCO shall record modifications made to the standard Sample collection procedures for *Athlete*s with impairments, including any applicable modifications specified in the above actions.

ANNEX B – MODIFICATIONS FOR *ATHLETE*S WHO ARE MINORS

B.1. **Objective**

To ensure, where possible, that the particular needs of *Athlete*s who are Minors are met in relation to the provision of a Samplewithout compromising the integrity of the Sample Collection Session.

B.2. **Scope**

Determining whether modifications are necessary starts with identification of situations where Sample collection involves *Athlete*s who are Minors and ends with modifications to Sample collection procedures where necessary and where possible.

B.3. **Responsibility**

B.3.1 NADO Italia has responsibility for ensuring, when possible, that the *Sample* Collection Authority and/or the DCO has any information necessary to conduct a *Sample* Collection Session with an *Athlete* who is a Minor. This includes confirming wherever necessary the parental consent for Testing any participating *Athlete* who is a Minor.

B.3.2 Where *Sample* collection involves an *Athlete* who is a *Minor*, NADO Italia and/or the Sample Collection Authority shall assign, at a minimum, two *Sample* Collection Personnel to the *Sample* Collection Session. *Sample* Collection Personnel shall be informed, in advance, that *Sample* collection involves (or may involve) *Athletes* who are *Minors*.

B.3.3 The DCO has responsibility for Sample collection.

B.4. **Requirements**

B.4.1 All aspects of notification and Sample collection for *Athlete*s who are Minors shall be carried out in accordance with the standard notification and Sample collection procedures unless modifications are necessary due to the *Athlete* being a Minor.

B.4.2 The Sample Collection Authority and the DCO shall have the authority to make modifications as the situation requires as long as such modifications will not compromise the integrity, identity and security of the *Sample*. All such modifications shall be documented.

B.4.3 *Athlete*s who are Minors should be notified in the presence of an *Athlete* representative (who is not a Minor) and should also be accompanied by a representative throughout the entire Sample Collection Session.

B.4.4 Should an *Athlete* who is a *Minor* decline to have a representative present during the collection of a *Sample*, thisdoes not invalidate the Test, but shall beclearly documented by the DCO. Any follow up action taken by the DCO and/or Chaperone to encourage and assist the Athlete in locating a representative should also be documented..

B.4.5 The representative of the *Minor* if present shall observe the DCO/Chaperone during the passing of the urine Sample, unless requested by the *Minor* to observe the passing of the urine Sample directly. The second member of the Sample Collection Personnel shall only observe the DCO and shall not directly observe the passing of the Sample.

B.4.6 The preferred venue for all Out-of-Competition Testing of a Minor is a location where the presence of an *Athlete* representative (who is not a Minor) is most likely to be available for the duration of the Sample Collection Session, e.g., a training venue.

ANNEX C – COLLECTION OF URINE SAMPLES

C.1. Objective

To collect an *Athlete*'s urine *Sample* in a manner that ensures:

a) Consistency with relevant principles of internationally recognized standard precautions in healthcare settings so that the health and safety of the *Athlete* and Sample Collection Personnel are not compromised;

b) The *Sample* meets the Suitable Specific Gravity for Analysis and the Suitable Volume of Urine for Analysis. Failure of a *Sample* to meet these requirements in no way invalidates the suitability of the *Sample* for analysis. The determination of a *Sample*'s suitability for analysis is the decision of the relevant Laboratory, in consultation with the Testing Authority for the Sample Collection Session in question;

c) the *Sample* has not been manipulated, substituted, contaminated or otherwise tampered with in any way;

d) the *Sample* is clearly and accurately identified; and

e) the *Sample* is securely sealed in a Tamper Evident kit.

C.2. Scope

The collection of a urine *Sample* begins with ensuring the *Athlete* is informed of the *Sample* collection requirements and ends with discarding any residual urine remaining at the end of the *Athlete*'s Sample Collection Session.

C.3. Responsibility

C.3.1 The DCO has the responsibility for ensuring that each *Sample* is properly collected, identified and sealed.

C.3.2 The DCO has the responsibility for directly witnessing the passing of the urine *Sample*.

C.4. Requirements

C.4.1 The DCO shall ensure that the *Athlete* is informed of the requirements of the Sample Collection Session, including any modifications as provided for in Annex A – Modifications for *Athlete*s with Impairments and/or in Annex B – Modifications for *Athletes* who are *Minors*.

C.4.2 The DCO shall ensure that the *Athlete* is offered a choice of *Sample* collection vessels for collecting the *Sample*. If the nature of an *Athlete*'s impairment requires that they must use additional or other equipment as provided for in Annex A - Modifications for *Athlete*s with Impairments, the DCO shall inspect that equipment to ensure that it will not affect

the integrity, identity or security of the *Sample*.

C.4.3 When the *Athlete* selects a collection vessel, and for selection of all other Sample Collection Equipment that directly holds the urine *Sample*, the DCO will instruct the *Athlete* to check that all seals on the selected equipment are intact and the equipment has not been tampered with. If the *Athlete* is not satisfied with the selected equipment, they may select another. If the *Athlete* is not satisfied with any of the equipment available for selection, this shall be recorded by the DCO. If the DCO does not agree with the *Athlete* that all of the equipment available for the selection is unsatisfactory, the DCO shall instruct the *Athlete* to proceed with the Sample Collection Session. If the DCO agrees with the *Athlete* that all of the equipment available for the selection is unsatisfactory, the DCO shall terminate the urine Sample collection, and this shall be recorded by the DCO.

C.4.4 The *Athlete* shall retain control of the collection vessel and any *Sample* provided until the *Sample* (or partial *Sample*) is sealed, unless assistance is required by reason of an *Athlete*'s impairment as provided for in Annex A - Modifications for *Athlete*s with Impairments. Additional assistance may be provided in exceptional circumstances to any *Athlete* by the *Athlete*'s representative or Sample Collection Personnel during the Sample Collection Session where authorized by the *Athlete* and agreed to by the DCO.

C.4.5 The DCO/Chaperone who witnesses the passing of the *Sample* shall be of the same gender as the *Athlete* providing the *Sample* and where applicable, based on the gender of the Event the *Athlete* competed in.

C.4.6 The DCO/Chaperone shall, where practicable, ensure the *Athlete* thoroughly washes their hands with water only prior to the provision of the *Sample* or wears suitable (e.g., disposable) gloves during provision of the *Sample*.

C.4.7 The DCO/Chaperone and *Athlete* shall proceed to an area of privacy to collect a *Sample*.

C.4.8 The DCO shall ensure an unobstructed view of the *Sample* leaving the *Athlete*'s body and shall continue to observe the *Sample* after provision until the *Sample* is securely sealed. In order to ensure a clear and unobstructed view of the passing of the *Sample*, the DCO shall instruct the *Athlete* to remove or adjust any clothing which restricts the DCO's clear view of *Sample* provision.

C.4.9 The DCO shall ensure that urine passed by the *Athlete* is collected in the collection vessel to its maximum capacity and thereafter the *Athlete* is encouraged to fully empty their bladder into the toilet. The DCO shall verify, in full view of the *Athlete*, that the Suitable Volume of Urine for Analysis has been provided.

C.4.10 Where the volume of urine provided by the *Athlete* is insufficient, the DCO shall follow the partial *Sample* collection procedure set out in Annex E - Urine *Sample*s - Insufficient Volume.

C.4.11 Once the volume of urine provided by the *Athlete* is sufficient, the DCO shall instruct the *Athlete* to select a *Sample* collection kit containing A and B bottles or containers in accordance with Annex C.4.3.

C.4.12 Once a *Sample* collection kit has been selected, the DCO and the *Athlete* shall check that all *Sample* code numbers match and that this code number is recorded accurately by the DCO on the Doping Control form. If the *Athlete* or DCO finds that the numbers are not the same, the DCO shall instruct the *Athlete* to choose another kit in accordance with Annex C.4.3. The DCO shall record the matter.

C.4.13 The *Athlete* shall pour the minimum Suitable Volume of Urine for Analysis into the B bottle or container (to a minimum of 30 mL), and then pour the remainder of the urine into the A bottle or container (to a minimum of 60 mL). The Suitable Volume of Urine for Analysis shall be viewed as an absolute minimum. If more than the minimum Suitable Volume of Urine for Analysis has been provided, the DCO shall ensure that the *Athlete* fills the A bottle or container to capacity as per the recommendation of the equipment manufacturer. Should there still be urine remaining, the DCO shall ensure that the *Athlete* fills the B bottle or container to capacity as per the recommendation of the equipment manufacturer. The DCO shall instruct the *Athlete* to ensure that a small amount of urine is left in the collection vessel, explaining that this is to enable the DCO to test the residual urine in accordance with Annex C.4.15.

C.4.14 The *Athlete* shall then seal the A and B bottles or containers as directed by the DCO. The DCO shall check, in full view of the *Athlete*, that the bottles or containers have been properly sealed.

C.4.15 The DCO shall test the residual urine in the collection vessel to determine if the *Sample* has a Suitable Specific Gravity for Analysis. If the DCO's field reading indicates that the *Sample* does not have a Suitable Specific Gravity for Analysis, then the DCO shall follow Annex F - Urine *Sample*s that do not meet the requirement for Suitable Specific Gravity for Analysis.

C.4.16 Urine should only be discarded when both the A and B bottles or containers have been sealed and the residual urine has been tested in accordance with Annex C.4.15.

C.4.17 The *Athlete* shall be given the option of witnessing the discarding of any residual urine that will not be sent for analysis.

ANNEX D – COLLECTION OF VENUS BLOOD SAMPLES

D.1. Objective

To collect an *Athlete*'s blood *Sample* by venipuncture in a manner that ensures:

a) Consistency with relevant principles of internationally recognized standard precautions in healthcare settings, and is collected by a suitably qualified Person, so that the health and safety of the *Athlete* and Sample Collection Personnel are not compromised;

b) The *Sample* is of a quality and quantity that meets the relevant analytical guidelines and requirements defined by the Laboratory;

c) The *Sample* has not been manipulated, substituted, contaminated or otherwise tampered with in any way;

d) The *Sample* is clearly and accurately identified; and

e) The *Sample* is securely sealed in a Tamper Evident kit.

D.2. Scope

The requirements of this Annex apply to venous blood *Samples* collected for the purposes of specific analysis and/or all modules of the *Athlete Biological Passport*. The collection of a blood *Sample* begins with ensuring the *Athlete* is informed of the *Sample* collection requirements and ends with properly storing the *Sample* prior to transport to the Laboratory that will be analyzing the *Sample*.

D.3. Responsibility

D.3.1 The DCO has the responsibility for ensuring that:

a) Each *Sample* is properly collected, identified and sealed; and

b) All *Samples* have been properly stored and dispatched in accordance with the relevant analytical guidelines.

c) If a blood *Sample* is to be collected in a serum tube from the *Athlete*, *Sample* collection shall not occur within sixty (60) minutes of the *Athlete*'s training, participation in Competition or other similar physical activity. If the *Athlete* has trained or competed less than sixty (60) minutes before the time the *Athlete* has been notified of their selection, the DCO or other designated Sample Collection Personnel shall keep the *Athlete* under direct observation until this 60-minute period has elapsed. The same applies for whole blood *Samples* analyzed for the Hematological Module of the *Athlete Biological Passport* in line with ISTI Annex I.2.1 and I.2.2. The DCO shall document on the Blood Collection Supplementary Report Form whether the *Athlete* was engaged in any type of physical activity prior to *Sample* collection and if so record that

the *Athlete* waited the required sixty (60) minutes prior to *Sample* collection. This information shall be made available to the Laboratory.

D.3.2 The BCO has the responsibility for collecting the blood *Sample*, answering related questions during the provision of the *Sample*, and proper disposal of used blood sampling equipment not required to complete the Sample Collection Session.

[Comment to Annex D.3.1 c): Part of the sixty (60) minute wait includes the Athlete sitting in an upright stationary position with their feet on the floor for at least ten (10) minutes as outlined in Article D.4.5. The sixty (60) minute wait does not apply to whole blood Samples collected in EDTA tubes that will not be analyzed for the Hematological Module of the Athlete Biological Passport.]

D.4. Requirements

D.4.1 Procedures involving blood shall be consistent with the local standards and regulatory requirements regarding precautions in healthcare settings where those standards and requirements exceed the requirements set out below.

D.4.2 Blood Sample Collection Equipment shall consist of:

a) Collection tube(s); and/or

b) A and B bottles/containers for the secure transportation of collection tube(s); and/or

c) Unique labels for collection tube(s) with a *Sample* code number; and/or

d) Such other types of equipment to be used in connection with the collection of blood as set out in Article 6.3.4 and WADA's *Sample* Collection Guidelines.

D.4.3 The DCO shall ensure that the *Athlete* is properly notified of the requirements of the *Sample* collection, including any modifications as provided for in Annex A - Modifications for *Athlete*s with Impairments.

D.4.4 The DCO/Chaperone and *Athlete* shall proceed to the area where the *Sample* will be provided.

D.4.5 The DCO/BCO shall ensure the *Athlete* is offered comfortable conditions and shall instruct the *Athlete* to remain in an upright, stationary seated position with feet on the floor for at least 10 minutes prior to providing a blood *Sample*. . If the *Athlete*'s feet cannot reach the floor and/or the *Athlete*'s impairment does not allow feet on the floor, the *Athlete* shall remain in an upright, stationary seated position.

D.4.6 The DCO/BCO shall instruct the *Athlete* to select the *Sample* Collection Equipment required for collecting the *Sample* and to check that the selected equipment has not been tampered with and any seals are intact. If the *Athlete* is not satisfied with the selected equipment, they may select another. If the *Athlete* is not satisfied with any equipment and no other is available, this shall be recorded by the DCO. If the DCO does not agree with the *Athlete* that all of the available equipment is unsatisfactory, the DCO shall instruct the *Athlete* to proceed with the Sample Collection Session. If the DCO agrees with the *Athlete* that all available equipment is

unsatisfactory, the DCO shall terminate the blood Sample collection and this shall be recorded by the DCO.

D.4.7 When a *Sample* collection kit has been selected, the DCO and the *Athlete* shall check that all *Sample* code numbers match and that this *Sample* code number is recorded accurately by the DCO on the Doping Control form. If the *Athlete* or DCO finds that the numbers are not the same, the DCO shall instruct the *Athlete* to choose another kit. The DCO shall record the matter. If the collection tube(s) are not pre-labelled, the DCO/BCO shall label them with a unique *Sample* code number prior to the blood being drawn and the *Athlete* shall check that the code numbers match.

D.4.8 The BCO shall assess the most suitable location for venipuncture that is unlikely to adversely affect the *Athlete* or their performance. This should be the non-dominant arm, unless the BCO assesses the other arm to be more suitable. The BCO shall clean the skin with a sterile disinfectant wipe or swab and, if required apply a tourniquet. The BCO shall take the blood *Sample* from a superficial vein into the tube. The tourniquet, if applied, shall be immediately removed after the venipuncture has been made.

D.4.9 The amount of blood removed shall be adequate to satisfy the relevant analytical requirements for the *Sample* analysis to be performed, as set out in WADA's *Sample* Collection Guidelines.

D.4.10 If the amount of blood that can be removed from the *Athlete* at the first attempt is insufficient, the BCO shall repeat the procedure up to a maximum of three (3) attempts in total. Should all three (3) attempts fail to produce a sufficient amount of blood, then the BCO shall inform the DCO. The DCO shall terminate the blood *Sample* collection and record the reasons for terminating.

D.4.11 The BCO shall apply a dressing to the puncture site(s).

D.4.12 The BCO shall dispose of used blood sampling equipment not required to complete the Sample Collection Session in accordance with the required local standards for handling blood.

D.4.13 After the blood flow into the tube ceases, the BCO shall remove the tube from the holder and homogenize the blood in the tube manually by inverting the tube gently at least three (3) times). The *Athlete* shall remain in the blood collection area and observe their *Sample* until it is sealed in a Tamper Evident kit.

D.4.14 The *Athlete* shall seal their *Sample* into a Tamper Evident kit as directed by the DCO. In full view of the *Athlete*, the DCO shall check that the sealing is satisfactory. The *Athlete* and the BCO/DCO shall sign the Doping Control form.

D.4.15 The sealed *Sample* shall be stored in a manner that protects its integrity, identity and security prior to transport from the Doping Control Station to the Laboratory that will be analyzing the *Sample*.

D.4.16 Blood *Samples* shall be transported in accordance with Article 9 and WADA's *Sample* Collection Guidelines. The transport procedure is the responsibility of the DCO. Blood *Samples* shall be

transported in a device that maintains the integrity of *Samples* over time, in a cool and constant environment, measured by a temperature data logger notwithstanding changes in external temperature. The transport device shall be transported by secure means using a method authorized by NADO Italia or Sample Collection Authority.

ANNEX E – URINE SAMPLES – INSUFFICIENT VOLUME

E.1. Objective

To ensure that where a Suitable Volume of Urine for Analysis is not provided, appropriate procedures are followed.

E.2. Scope

The procedure begins with informing the *Athlete* that the *Sample* that they have provided is not of Suitable Volume of Urine for Analysis and ends with the *Athlete*'s provision of a *Sample* of sufficient volume.

E.3. Responsibility

The DCO has the responsibility for declaring the *Sample* volume insufficient and for collecting the additional *Sample*(*s*) to obtain a combined *Sample* of sufficient volume.

E.4. Requirements

E.4.1 If the *Sample* collected is of insufficient volume, the DCO shall inform the *Athlete* that a further *Sample* shall be collected to meet the Suitable Volume of Urine for Analysis requirements.

E.4.2 The DCO shall instruct the *Athlete* to select partial Sample Collection Equipment in accordance with Annex C.4.3.

E.4.3 The DCO shall then instruct the *Athlete* to open the relevant equipment, pour the insufficient *Sample* into the new container (unless the Sample Collection Authority's procedures permit retention of the insufficient *Sample* in the original collection vessel) and seal it using a partial *Sample* sealing system, as directed by the DCO. The DCO shall check, in full view of the *Athlete*, that the container (or original collection vessel, if applicable) has been properly sealed.

E.4.4 The DCO shall record the partial *Sample* number and the volume of the insufficient *Sample* on the Doping Control form and confirm its accuracy with the *Athlete*. The DCO shall retain control of the sealed partial *Sample*.

E.4.5 While waiting to provide an additional *Sample*, the *Athlete* shall remain under continuous observation and be given the opportunity to hydrate in accordance with Article 8.3.

E.4.6 When the *Athlete* is able to provide an additional *Sample*, the procedures for collection of the *Sample* shall be repeated as prescribed in Annex C - Collection of Urine *Samples*, until a sufficient volume of urine will be provided by combining the initial and additional *Sample*(*s*).

E.4.7 Following each *Sample* provided, the DCO and *Athlete* shall check the integrity of the seal(s) on the container(s) containing the previously provided partial *Sample*(*s*). Any irregularity with the integrity of the seal(s) will be recorded by the DCO and investigated according to Annex A – Review of a Possible Failure to Comply of the *Results Management Procedure*. The DCO may request that an additional *Sample* is collected from the *Athlete*. A refusal to provide a further *Sample* if requested, where the minimum requirements for *Sample* collection volume are not met, shall be recorded by the DCO and dealt with as a potential Failure to Comply in accordance with the International Standard for Results Management.

E.4.8 The DCO shall then direct the *Athlete* to break the seal(s) and combine the *Samples*, ensuring that additional *Samples* are added in the order they were collected to the original partial *Sample* until, as a minimum, the requirement for Suitable Volume of Urine for Analysis is met.

E.4.9 The DCO and the *Athlete* shall then continue with Annex C.4.12 or Annex C.4.14 as appropriate.

ANNEX F – URINE SAMPLES THAT DO NOT MEET THE REQUIREMENT FOR SUITABLE SPECIFIC GRAVITY FOR ANALYSIS

F.1. **Objective**

To ensure that when the urine *Sample* does not meet the requirement for Suitable Specific Gravity for Analysis, appropriate procedures are followed.

F.2. **Scope**

The procedure begins with the DCO informing the *Athlete* that a further *Sample* is required and ends with the collection of a *Sample* that meets the requirements for Suitable Specific Gravity for Analysis, or appropriate follow-up action by NADO Italia if required.

F.3. **Responsibility**

F.3.1 The Sample Collection Authority is responsible for establishing procedures to ensure that a suitable *Sample* is collected, if the original *Sample* collected does not meet the requirement for Suitable Specific Gravity for Analysis.

F.3.2 The DCO is responsible for collecting additional *Samples* until a suitable *Sample* is obtained.

F.4. **Requirements**

F.4.1 The DCO shall determine that the requirements for Suitable Specific Gravity for Analysis have not been met.

F.4.2 The DCO shall inform the *Athlete* that they are required to provide a further *Sample.*

F.4.3 While waiting to provide a further *Sample*, the *Athlete* shall remain under continuous observation and shall be advised not to hydrate, since this may delay the production of a suitable *Sample*. In appropriate circumstances, further hydration after the provision of an unsuitable *Sample* may be pursued as a violation of Code Article 2.5.

F.4.4 When the *Athlete* is able to provide an additional *Sample*, the DCO shall repeat the procedures for *Sample* collection set out in Annex C - Collection of Urine *Samples.*

F.4.5 The DCO shall continue to collect additional Samples until the requirement for Suitable Specific Gravity for Analysis is met, or until the DCO determines that there are exceptional circumstances which mean it is impossible to continue with the Sample Collection Session. Such exceptional circumstances shall be documented accordingly by the DCO and described on the Supplementary Report Form. They may include:

- Athlete travel, if the athlete provides proof of travel (i.e., flight itinerary);
- Early morning competition, if it is getting late and the athlete is competing again in the morning;
- Closing of venue, if the venue is closing and there are no other location options available (i.e., athlete accommodation, etc.).

The Sample Collection Authority and DCOs should ensure they have adequate equipment to comply with the requirements of this Annex. The DCO should wait as long as necessary to collect such additional Sample(s) with a Suitable Specific Gravity for Analysis.

F.4.6 The DCO shall record that the *Samples* collected belong to a single *Athlete* and the order in which the *Samples* were provided.

F.4.7 The DCO shall then continue with the Sample Collection Session in accordance with Annex C.4.17.

F.4.8 The DCO shall send to the Laboratory for analysis all *Samples* which were collected, irrespective of whether or not they meet the requirement for Suitable Specific Gravity for Analysis.

F.4.9 When two (2) *Samples* are collected from an *Athlete*, during the same Sample Collection Session, both Samples shall be analyzed by the Laboratory. In cases where three (3) or more Samples are collected during the same Sample Collection Session, the Laboratory shall prioritize and analyze the first and the subsequent collected *Sample* with the highest specific gravity, as recorded on the Doping Control form. The Laboratory, in conjunction with the Testing Authority, may determine if the other *Samples* need to be analyzed.

ANNEX G – SAMPLE COLLECTION PERSONNEL REQUIREMENTS

G.1 Objective

To ensure that Sample Collection Personnel have no conflict of interest and have adequate qualifications and experience to conduct Sample Collection Sessions.

G.2 Scope

Sample Collection Personnel requirements start with the development of the necessary competencies for Sample Collection Personnel and end with the provision of identifiable accreditation.

G.3 Responsibility

The Sample Collection Authority has the responsibility for all activities defined in this Annex.

G.4 Requirements - Qualifications andTraining

G.4.1 The Sample Collection Authority shall:

a) Determine the necessary competence, eligibility and qualification requirements for the positions of DCO, Chaperone and BCO; and

b) Develop duty statements for all Sample Collection Personnel that outline their respective responsibilities. As a minimum:

- Sample Collection Personnel shall not be *Minors*; and

- BCOs shall have adequate qualifications and practical skills required to perform blood collection from a vein.

G.4.2 The Sample Collection Authority shall ensure that Sample Collection Personnel sign an agreement dealing with conflicts of interest, confidentiality and code of conduct.

G.4.3 Sample Collection Personnel shall not be appointed to a Sample Collection Session where they have an interest in the outcome of a Sample Collection Session. At a minimum, Sample Collection Personnel are deemed to have such an interest if they are:

- Involved in the participation or administration of the sport at the level for which *Testing* is being conducted;

- Related to, or involved in the personal affairs of, any *Athlete* who might provide a *Sample* at that Sample Collection Session;

- Have family members actively involved in the daily activities of the sport at the level for which *Testing* is being conducted (e.g., administration, coaching, training, officiating, competitor, medical);

- Are engaged in business with, have a financial interest in or personal stake in a sport that has *Athletes* who are subject to *Testing*;

- Are drawing or likely to draw personal and/or professional gain or advantage directly or indirectly from a third party due to their own decisions taken in the fulfillment of their official functions; and/or

- Appear to have private or personal interests that detract from their ability to perform their duties with integrity in an independent and purposeful manner.

G.4.4 The Sample Collection Authority shall establish a system that ensures that *Sample* Collection Personnel are adequately trained to carry out their duties.

G.4.4.1 The training program for BCOs shall include, as a minimum, studies of all relevant requirements of the *Testing* process and familiarization with relevant standard precautions in healthcare settings.

G.4.4.2 The training program for DCOs shall include, as a minimum:

- Comprehensive theoretical training in those *Doping Control* activities relevant to the DCO position;
- Observation of all Sample Collection Session activities that are the responsibility of the DCO as set out in this *International Standard* for *Testing* and Investigations, preferably on-site; and
- The satisfactory performance of one complete Sample Collection Session on-site under observation by a qualified DCO or similar. The requirement related to the actual passing of a urine *Sample* shall not be included in the on-site observations.

G.4.4.3 The training program for Chaperones shall include all relevant requirements of the Sample Collection Session including but not limited to situations dealing with Failure to Comply, *Athletes* who are *Minors* and/or *Athletes* with impairments.

G.4.4.4 A Sample Collection Authority that collects *Samples* from *Athletes* who are of a different nationality to its Sample Collection Personnel (e.g., at an *International Event* or in an *Out-of-Competition* context) should ensure that such Sample Collection Personnel are adequately trained to carry out their duties in respect of such *Athletes*.

G.4.4.45 The Sample Collection Authority shall maintain records of education, training, skills and experience of all Sample Collection Personnel.

G.5 Requirements - Accreditation, Re-Accreditation and Delegation

G.5.1 The Sample Collection Authority shall establish a system for accrediting and re-accrediting Sample Collection Personnel.

G.5.2 The Sample Collection Authority shall ensure that Sample Collection Personnel have completed the training program and are familiar with the requirements of this *International Standard* for *Testing* and Investigations (including, where G.4.4.4 applies, in relation to the collection of *Samples* from *Athletes* who are of a different nationality than the Sample Collection Personnel) before granting accreditation.

G.5.3 Accreditation shall only be valid for a maximum of two (2) years. Sample Collection Personnel shall be subject to an assessment (theoretical and/or practical) before being re- accredited and shall be required to repeat a full training program if they have not participated in *Sample* collection activities within the year prior to re-accreditation.

G.5.4 Only Sample Collection Personnel who have an accreditation recognized by the Sample Collection Authority shall be authorized to conduct *Sample* collection activities on behalf of the Sample Collection Authority.

G.5.5 The Sample Collection Authority shall develop a system to monitor the performance of Sample Collection Personnel during the period of accreditation, including defining and implementing criteria for revoking accreditation.

G.5.6 DCOs may personally perform any activities involved in the Sample Collection Session, with the exception of blood collection unless particularly qualified, or they may direct a Chaperone to perform specified activities that fall within the scope of the Chaperone's authorized duties as determined by the Sample Collection Authority

ANNEX H – EVENT TESTING

H.1. Objective

To ensure there is a procedure to follow when a request is made by an *Anti-Doping Organization* for permission to conduct *Testing* at an *Event* where they have been unable to reach agreement on such *Testing* with the ruling body of the *Event*. *WADA*'s objective in considering such requests is to:

a) Encourage collaboration and coordination between different *Anti-Doping Organizations* to optimize the effectiveness of their respective *Testing* programs;

b) Ensure that each *Anti-Doping Organization*'s responsibilities are properly managed; and

c) Avoid creating operational disturbance and harassment for *Athletes*.

H.2. Scope

The procedure starts with the *Anti-Doping Organization* that is not responsible for initiating or directing *Testing* at an *Event* contacting the ruling body of the *Event* in writing to seek permission to conduct *Testing* and ends with *WADA* issuing a decision as to who shall be responsible to conduct *Testing* at the *Event*.

H.3. Responsibility

Both *Anti-Doping Organizations* seeking permission to conduct *Testing* at an *Event* and the ruling body of the *Event* should collaborate and where possible coordinate *Testing* at the *Event*. However, if this is not possible, then both *Anti-Doping Organizations* are required to submit their reasonings to *WADA* within the timeframes outlined. *WADA* then has the responsibility of reviewing the circumstances and issuing a decision in accordance with the procedures set out in this Annex.

H.4. Requirements

Any *Anti-Doping Organization* that is not responsible for initiating and directing *Testing* at an *Event* in accordance with *Code* Article 5.3.2, but which nevertheless desires to conduct *Testing* at such *Event* shall, prior to contacting *WADA*, request such permission from the ruling body of the *Event* in written form with full supporting reasons.

H.4.1. Such request shall be sent to the ruling body at least thirty-five (35) days prior to the beginning of the *Event* (i.e., thirty-five (35) days prior to the beginning of the *In-Competition* period as defined by the rules of the International Federation in charge of that sport).

H.4.2. If the ruling body refuses or does not respond within seven (7) days from receipt of the request, the requesting *Anti-Doping Organization* may send to *WADA* (with a copy to the ruling body) a written request with full supporting reasons, a clear description of the situation, and all the relevant correspondence between the ruling body and the requesting *Anti-Doping Organization*. Such request must be received by WADA no later than twenty-one (21) days prior to the beginning of the *Event*.

H.4.3 Upon receipt of such request, *WADA* will immediately ask the ruling body for its position on the request and the grounds for its refusal. The ruling body shall send *WADA* an answer within seven (7) days of receipt of *WADA*'s request.

H.4.4 Upon receipt by *WADA* of the ruling body's answer, or if no answer is provided by the ruling body within the seven (7) days, *WADA* will render a reasoned decision within the next seven (7) days. In making its decision, *WADA* will consider, amongst others, the following:

a) The Test Distribution Plan for the *Event*, including the number and type of *Testing* planned

for the *Event*;
b) The menu of *Prohibited Substances* for which the *Samples* collected will be analyzed;
c) The overall anti-doping program applied in the sport;
d) The logistical issues that would be created by allowing the requesting *Anti-Doping Organization* to conduct *Testing* at the *Event*;
e) Any other grounds submitted by the requesting *Anti-Doping Organization* and/or the ruling body refusing such *Testing*; and
f) Any other available information that *WADA* considers relevant.

H.4.5 If an *Anti-Doping Organization* who is not the ruling body for an *Event* in the country in which the *Event* is being hosted, has or receives intelligence regarding potential doping by an *Athlete*(s) who is due to compete at the *Event*, the *Anti-Doping Organization* shall share the intelligence with the ruling body of the *Event* as soon as possible. If no *Testing* is planned by the ruling body for the *Event* and the *Anti-Doping Organization* is in a position to conduct *Testing* itself, the ruling body for the *Event* shall assess whether it or the *Anti-Doping Organization* can conduct *Testing* regardless of whether the intelligence is provided by the *Anti-Doping Organization* within the thirty-five (35) day period preceding the *Event*. If the ruling body of the *Event* fails to engage with the *Anti-Doping Organization* that provided the intelligence or decides it is not able to conduct *Testing* itself or does not authorize the *Anti-Doping Organization* to conduct Testing at the *Event*, then the *Anti-Doping Organization* shall notify *WADA* immediately.

H.4.6 If *WADA* decides that permission for *Testing* at the *Event* should be granted, either as requested by the requesting *Anti-Doping Organization* or as proposed by *WADA*, *WADA* may give the ruling body the possibility of conducting such *Testing*, unless *WADA* judges that this is not realistic and/or appropriate in the circumstances.

ANNEX I – COLLECTION, STORAGEAND TRANSPORT OF BLOOD *ATHLETE* BIOLOGICAL PASSPORT SAMPLES

I.1. Objective

To collect an *Athlete*'s blood *Sample* by venipuncture, intended for use in connection with the measurement of individual *Athlete* blood variables within the framework of the hematological module of the *Athlete* Biological Passport program, in a manner appropriate for such use. The requirements of this Annex are additional requirements to those contained in Annex D – Collection of Venous Blood *Samples*.

I.2. Requirements

I.2.1 Planning shall consider the *Athlete*'s whereabouts information to ensure *Sample* collection does not occur within sixty (60) minutes of the *Athlete*'s training, participation in Competition or other similar physical activity. If the *Athlete* has trained or competed less than sixty (60) minutes before the time the *Athlete* has been notified of their selection, the DCO or other designated Sample Collection Personnel shall chaperone the *Athlete* until this sixty (60) minutes period has elapsed.

I.2.2 If the *Sample* was collected within sixty (60) minutes of training or Competition, the nature, duration and intensity of the exertion shall be recorded by the DCO to make this information available to the APMU.

I.2.3 Although a single blood *Sample* is sufficient within the framework of the hematological module of the *Athlete* Biological Passport, it is recommended to collect an additional B *Sample* for a possible subsequent analysis of Prohibited Substances and Prohibited Methods in whole blood (e.g., detection of homologous blood transfusion (HBT) and/or erythropoietin receptor agonists (ERAs)).

I.2.4 For Out-of-Competition Testing, A and B urine *Samples* should be collected together with the blood *Athlete Biological Passport Sample*(*s*) in order to permit Analytical Testing for ERAs unless otherwise justified by a specific intelligent Testing strategy.

I.2.5 The *Sample* shall be refrigerated from its collection until its analysis with the exception of when the *Sample* is analyzed immediately following collection. The storage procedure is the DCO's responsibility.

I.2.6 The storage and transport device shall be capable of maintaining blood Athlete Biological Passport *Samples* at a cool temperature during storage. Whole blood *Samples* shall not be allowed to freeze at any time. In choosing the storage and transport device, the DCO shall take into account the time of storage, the number of *Samples* to be stored in the device and the prevailing environmental conditions (hot or cold temperatures). The storage device shall be one of the following:

a) Refrigerator;
b) Insulated cool box;
c) Isotherm bag; or
d) Any other device that possesses the capabilities mentioned above.

I.2.7 A temperature data logger shall be used to record the temperature from the collection to the analysis of the *Sample* except when the *Sample* is analyzed immediately following collection.

The temperature data logger shall be able to:

a) Record the temperature in degrees Celsius at least once per minute;

b) Record time in GMT;
c) Report the temperature profile over time in text format with one line per measurement following the format "YYYY-MM-DD HH:MM T"; and
d) Have a unique ID of at least six characters.

I.2.8 Following notification to the *Athlete* that they have been selected for *Sample* collection and following the DCO/BCO's explanation of the *Athlete*'s rights and responsibilities in the *Sample* collection process, the DCO/BCO shall ask the *Athlete* to remain still, in an upright, stationary seated position, with feet on the floor for at least ten (10) minutes prior to providing a blood *Sample*. If the *Athlete*'s feet cannot reach the floor and/or the *Athlete*'s impairment does not allow feet on the floor, the *Athlete* shall remain in an upright, stationary seated position.

I.2.9 The DCO/BCO shall collect and record the following additional information on a Blood Collection Supplementary Report Form, *Athlete* Biological Passport specific *Doping Control* form or other related report form to be signed by the *Athlete* and the DCO/BCO:

a) Has the *Athlete* been seated for at least ten (10) minutes with their feet on the floor prior to blood collection, as per I.2.8?

b) Was the *Sample* collected immediately following at least three (3) consecutive days of an intensive endurance Competition, such as a stage race in cycling?

c) Will the *Athlete* be competing within the next three (3) days (including today)?

d) Has the *Athlete* had a training session or Competition in the sixty (60) minutes prior to the blood collection?

e) Did the *Athlete* train, compete or reside at an altitude greater than 1,500 meters within the prior four (4) weeks? If so, or if in doubt, the name and location of the place where the *Athlete* had been, and the dates and the duration of their stay shall be recorded. The estimated altitude shall be entered, if known.

f) Did the *Athlete* use any form of altitude simulation such as a hypoxic tent, mask, etc. during the prior four (4) weeks? If so, as much information as possible on the type of device and the manner in which it was used (e.g., frequency, duration, intensity) should be recorded.

g) Did the *Athlete* receive any blood transfusion(s) during the prior three (3) months? Was there any blood loss due to accident, pathology or donation in the prior three (3) months? If so, the estimated volume should be recorded.

h) Has the *Athlete* been exposed to any extreme environmental conditions during the last sixty (60) minutes prior to blood collection, including any sessions in any artificial heat environment, such as a sauna? If so, the details should be recorded.

I.2.10 The DCO/BCO shall start the temperature data logger and place it in the storage device. It is important to start recording the temperature before *Sample* collection.

I.2.11 The storage device shall be located in the Doping Control Station and shall be kept secure.

I.2.12 The DCO/BCO instructs the *Athlete* to select the *Sample* Collection Equipment in accordance with Annex D.4.6 and continue the *Sample* Collection Session in accordance with Annex D.4.7.

I.3. The *Sample* Collection Procedure

I.3.1 The *Sample* collection procedure for the collection of blood for the purposes of the *Athlete* Biological Passport is consistent with the procedure set out in Annex D.4, including the ten (10) minute (or more) seated period

I.3.2 The *Athlete* and the DCO/BCO sign the Doping Control and Blood Collection Supplementary Form(s), when applicable.

I.3.3 The blood *Sample* is sealed and deposited in the storage device containing the temperature data logger.

I.4. **Transportation Requirements**

I.4.1 Blood *Sample*s shall be transported in a device that maintains the integrity of *Samples* over time, due to changes in external temperature.

I.4.2 The transport procedure is the DCO's responsibility. The transport device shall be transported by secure means using a Sample Collection Authority authorized transport method.

I.4.3 The integrity of the Markers used in the hematological module of the *Athlete* Biological Passport is guaranteed when the Blood Stability Score (BSS) remains below eighty-five (85), where the BSS is computed as:
BSS = 3 * T + CAT
with CAT being the Collection to Analysis Time (in hours), and T the average Temperature (in degrees Celsius) measured by the data logger between *Sample* collection and analysis.

I.4.4 Within the framework of the BSS, the following table can be used by the DCO/BCO to estimate the maximal transport time to a Laboratory or ABP Laboratory for the *Athlete* Biological Passport, called the Collection to Reception Time (CRT), for a given average temperature (T), e.g., if shipped at 4°C, the maximal CRT is 60 h.:

T [°C]	CRT [h]
15	27
12	36
10	42
9	45
8	48
7	51
6	54
5	57
4	60

I.4.5 The DCO/BCO shall as soon as possible transport the *Sample* to a Laboratory or *ABP* Laboratory for the *Athlete* Biological Passport.

I.4.6 The Testing Authority or Sample Collection Authority shall report without delay into *ADAMS*:

a) The Doping Control form as per ISTI Article 4.9.1 b);

b) The Blood Collection Supplementary Form, and/or the additional information specific to the *Athlete* Biological Passport collected on a related report form;

c) In the Chain of Custody, the temperature data logger ID (without any time reference) and the time zone of the Testing location in GMT.

ANNEX J – COLLECTION, STORAGE AND TRANSPORT OF DRIED BLOOD SPOT *SAMPLES*

J.1 Objective

To collect an *Athlete*'s blood as a dried blood spot *Sample* in a manner that ensures:
a) consistency with relevant principles of internationally-recognized standard precautions in healthcare settings, and is collected by a suitably trained Person, so that the health and safety of the *Athlete* and *Sample* Collection Personnel are not compromised;
b) the *Sample* is of a quality and quantity that meets the relevant analytical requirements;
c) the *Sample* has not been manipulated, substituted, contaminated or otherwise tampered with in anyway;
d) the *Sample* is clearly and accurately identified; and
e) the *Sample* is securely sealed in a Tamper Evident kit.

J.2 Scope

The collection of a dried blood spot *Sample* begins with ensuring the *Athlete* is informed of the *Sample* collection requirements and ends with properly storing the *Sample* prior to transport to the Laboratory that will be analysing the *Sample*. Dried blood spot *Samples* are collected by puncture/incision of the skin to access capillary vessels (small blood vessels). One dried blood spot *Sample* consists of a series of small volumes of capillary blood, which are collected within the same *Sample* Collection Session and allowed to dry on an absorbent *Sample* support.

J.3 Responsibility

Due to the absence of venipuncture during dried blood spot collection, dried blood spot *Samples* may be collected by a DCO without the need for a specialized BCO if standard precautions in healthcare settings are followed and the DCO is suitably trained. Procedures for dried blood spot collection shall be consistent with local standards and regulatory requirements. The DCO and/or the BCO have the responsibility for:
a) Collecting the dried blood spot *Sample*;
b) Ensuring that each *Sample* is properly identified and sealed;
c) Answering relevant questions during the provision of the *Sample*;
d) Properly disposing of dried blood spot sampling equipment that is opened but not used, or used pieces of equipment not sealed with the absorbent *Sample* support; and
e) Properly storing and dispatching each *Sample*.

J.4 Requirements for Dried Blood Spot *Sample* Collection Equipment

The dried blood spot *Sample* Collection Equipment shall fulfill the following criteria:
a) contain a single-use *Sample* collection device (e.g., disposable lancets to be used in conjunction with cellulose cards, devices with integrated microneedle(s)/microlancet(s)) for the puncture/incision and collection of capillary blood at the fingertip and/or from the upper arm (alternative sites of punctures may be authorized for *Athletes* with physical impairments, if required);
b) the "A" and "B" absorbent *Sample* support shall allow the collection of distinct "A" and "B" spots (or equivalent) with a minimum total of approximately 40 µL of capillary blood in the "A" spot(s) and with a minimum total of approximately 20 µL of capillary blood in the "B" spot(s) and;
c) the *Sample* container and/or storage sleeves/packages/receptacles shall contain a desiccant to allow the spots to dry expeditiously when already sealed (without having to wait before sealing) and offering protection against possible premature degradation or contamination of the *Sample*.

J.5 **Dried Blood Spot *Sample* Provision**

Procedures involving blood collection shall be consistent with the local standards and regulatory requirements regarding precautions in healthcare settings where those standards and requirements exceed the requirements set out below.

J.5.1 The DCO shall ensure that the *Athlete* is properly notified of the requirements of the *Sample* collection, including any modifications as provided for in Annex A - Modifications for *Athletes* with Impairments and/or in Annex B - Modifications for *Athletes* who are *Minors*.

J.5.2 The DCO/Chaperone and *Athlete* shall proceed to the area where the *Sample* will be provided.

J.5.3 The DCO/BCO shall wear gloves during the *Sample* collection process and until the *Sample* is sealed.

J.5.4 The DCO/Chaperone shall, where practicable, ensure the *Athlete* thoroughly washes their hands with water only prior to the provision of the *Sample*.

J.5.5 The DCO/BCO shall ensure that the *Athlete* is offered comfortable conditions for the provision of the *Sample*.

J.5.6 The DCO/BCO shall instruct the *Athlete* to select the *Sample* Collection Equipment required for collecting the *Sample* and to check that the selected equipment has not been tampered with and any seals are intact. If the *Athlete* is not satisfied with the selected equipment, they may select another. If the *Athlete* is not satisfied with any equipment and no other is available, this shall be recorded by the DCO. If the DCO does not agree with the *Athlete* that all of the available equipment is unsatisfactory, the DCO shall instruct the *Athlete* to proceed with the *Sample* Collection Session. If the DCO agrees with the *Athlete* that all available equipment is unsatisfactory, the DCO shall terminate the collection of dried blood spot *Samples* and this shall be recorded by the DCO.

J.5.7 When a *Sample* collection kit has been selected, the DCO and the *Athlete* shall check that all *Sample* code numbers match and that this *Sample* code number is recorded accurately by the DCO on the Doping Control form. If the *Athlete* or DCO finds that the numbers are not the same, the DCO shall instruct the *Athlete* to choose another kit. The DCO shall record the matter.

J.5.8 The DCO/BCO shall assess the most suitable location for puncture at the fingertip and/or from the upper arm that is unlikely to adversely affect the *Athlete* or their sporting performance (e.g., non-dominant hand/arm). This should be a site of puncture that is free of any calluses, cuts, scars and tattoos. The DCO /BCO should select an alternative suitable site of puncture for *Athletes* with physical impairments if applicable.

J.5.9 The DCO/BCO shall instruct the *Athlete* to warm the *Sample* collection site by, for example, washing the hands in warm water, shaking the hand/arm, massaging the puncture site, or placing the hand/arm in a warm blanket or equivalent.

J.5.10 The DCO/BCO shall clean the skin with a sterile alcohol pad or swab. Disinfectant gels shall not be used. Once the skin is completely dried, the DCO/BCO shall take the capillary blood *Sample* from the fingertip or an area on the upper arm using the dried blood spot collection device in accordance with the instructions provided by the equipment

manufacturers.

For dried blood spot *Samples* collected from the fingertip:

a) The middle or ring finger should be selected if possible. The little finger may also be selected but the collection may be more painful;

b) The puncture should be done with a lancet, slightly lateral to the pad of the finger, on the last phalanx of the finger;

c) Blood flow can be increased by gently massaging the proximal portion of the finger in a distal direction. However, squeezing or milking the finger should be avoided as it may cause hemolysis and dilution of the *Sample*;

d) The first drop of blood shall be wiped away with a dry sterile compress/gauze pad;

e) Only the drop of blood shall enter into contact with the dried blood spot absorbent *Sample* support, while the finger shall not touch it. The drop of blood should not be smeared onto the absorbent *Sample* support; and

f) Only one drop of blood shall be applied per spot, because the dripping of several drops onto the same spot would cause an inhomogeneous *Sample*.

For dried blood spot *Samples* collected from the upper arm with a device with integrated microneedle(s)/microlancet(s):

g) The DCO/BCO shall be responsible for applying and removing the device from the *Athlete*'s arm. The *Athlete* is permitted to press the button to engage the microneedle(s)/microlancet(s) after having received the necessary instructions from the DCO/BCO. Otherwise, the DCO/BCO will press the button.

J.5.11 The volume of capillary blood removed shall be adequate to satisfy the relevant analytical requirements for the *Sample* analysis to be performed, i.e., a minimum total of approximately 40 µL of capillary blood in the "A" spot(s) and a minimum total of approximately 20 µL of capillary blood in the "B" spot(s) for chromatography-mass spectrometric Analytical Methods. Other special analyses may require additional *Samples* and/or increased *Sample* volume.

J.5.12 The DCO/BCO shall verify that capillary blood is deposited on the absorbent *Sample* support and that a sufficient number of spots in the "A" and "B" *Samples* (to produce a sufficient amount of capillary blood, as described in J.5.11) are saturated with blood. J.5.13 If the volume of capillary blood collected from the *Athlete* at the first attempt is insufficient, the DCO/BCO shall repeat the procedure up to a maximum of three (3) attempts in total. Should all three (3) attempts fail to produce a sufficient volume of capillary blood, the DCO shall terminate the collection of dried blood spot *Samples* and record the reasons for its termination. If more than one attempt is needed, another site of puncture shall be selected by the DCO/BCO. The skin shall be cleaned and a new lancet/*Sample* Collection device shall be used for the puncture of the skin.

J.5.14 After collection, the DCO/BCO shall apply pressure to the puncture site(s) or ask the *Athlete* to do so. The DCO/BCO shall then apply a dressing(s).

J.5.15 The DCO/BCO shall dispose of used pieces of equipment that are not sealed with the absorbent *Sample* support in accordance with the required local standards for handling blood.

J.5.16 If the *Sample* requires further on-site processing, such as removal of the absorbent *Sample* support (e.g., cellulose paper, cartridge) from the collection device, the DCO/BCO shall do so and then transfer the *Sample* into the Tamper Evident kit. The *Athlete* shall remain in the collection area and observe their *Sample* until it is sealed in a Tamper Evident kit.

J.5.17 The *Athlete* shall seal their *Sample* in the Tamper Evident kit as directed by the DCO. In full

view of the *Athlete*, the DCO shall check that the sealing is satisfactory. The *Athlete* and the DCO/BCO shall sign the *Sample* collection documentation; and

J.5.18 The sealed dried blood spot *Sample* can be stored at room temperature and shall be stored in a manner which minimizes the potential for *Sample* degradation due to factors such as time delays, exposure to light and extreme temperature variations.

J.6 Requirements for Transport

J.6.1 Dried blood spot *Samples* shall be transported in accordance with ISTI Articles 9.1 to 9.3, with the following specifications:

a) Dried blood spot *Samples* can be shipped as non-hazardous materials using regular mail or courier services, subject to any applicable regulations;
b) While the *Sample* containers shall be transparent, it is recommended to transport dried blood spot *Samples* in a non-transparent transport box/bag to protect the *Samples* from light exposure; and
c) Dried blood spot *Samples* can be transported at ambient temperature. If collecting other blood *Samples* (e.g., blood *Athlete* Biological Passport *Samples*) during the same *Sample* Collection Session, dried blood spot *Samples* can also be shipped refrigerated.

ANNEX K – COLLECTION OF URINE SAMPLES IN A VIRTUAL ENVIRONMENT DURING A PANDEMIC

K.1 **Objective**

To provide a modified *Sample* collection procedure in a virtual environment that may only be implemented during a pandemic and/or a national epidemic when local or national government health restrictions in place allow an in-person notification of an *Athlete* but restrict in-person collection of a urine sample by a DCO.

K.2 **Scope**

The procedure begins with the DCO notifying an *Athlete* at the testing location and handing the *Athlete* a package of *Sample* Collection Equipment and ends with the DCO collecting the sealed Sample and the corresponding Sample collection documentation from the *Athlete* at the location where notification to the *Athlete* of their selection for *Testing* and requirement to provide a *Sample* occurred, or at another location that the DCO and *Athlete* will agree to.

K.3 **Responsibility**

K.3.1 In times of a pandemic and/or a national epidemic, all *Anti-Doping Organizations* shall follow the advice of national governments and health authorities to ensure the health and safety of *Athlete*s and *Sample* Collection Personnel is protected. Specific requirements must be taken into consideration from any relevant international, national and regional laws when considering the implementation of *Sample* collection procedures (e.g., mandatory or recommended occupational health and safety practices such as social distancing, hand washing, mask wearing, vaccination etc.)

K.3.2 Prior to implementation, *Anti-Doping Organizations* shall assess modified *Sample* collection procedures in a virtual environment, including any selected IT system and any Third-Party Agent involved in such procedures or IT system, against the requirements of the International Standard for the Protection of Privacy and Personal Information and applicable laws, such as privacy/data protection and if necessary, shall implement appropriate physical, organizational, technical, and other measures to mitigate privacy and information security risks identified in such assessment.

K.3.3 The DCO has the responsibility for providing the *Athlete* with instructions from the point of the in-person notification and then virtually via the IT system used, and that each Sample is properly collected, identified, documented, sealed, and the integrity of the Sample is maintained throughout the virtual collection and sealing process.

K.4 **Requirements**

K.4.1 When initial contact is made, the DCO shall inform the *Athlete*, at the testing location, that they are required to undergo a Sample collection. The notification of the *Athlete* shall be in accordance with Article 5.4.1.

K.4.2 The DCO shall ensure that the *Athlete* is informed that the Sample collection and sealing procedure will be conducted in a virtual environment during their Sample Collection Session, including any modifications as provided for in Annex A - Modifications for *Athlete*s with Impairments and/or in Annex B - Modifications for *Athlete*s who are Minors.

K.4.3 The DCO shall complete the '*Athlete* Notification' part of the *Sample* collection documentation (either in paper or electronic) and the *Athlete* shall sign it to acknowledge and

accept the notification. If the *Athlete* refuses to sign that they have been notified, or evades the notification, the DCO shall, if possible, inform the *Athlete* of the Consequences of a Failure to Comply. The DCO shall document the facts in a detailed report and report the circumstances to the Testing Authority. The Testing Authority shall follow the steps prescribed in Annex A - Review of a Possible Failure to Comply of the International Standard for Results Management.

K.4.4 The DCO shall start a two-way video and audio connection via the selected IT system (e.g., tablet, mobile phone, or body camera) with supporting mounting device (if applicable) and provide it to the *Athlete*. The DCO shall advise the *Athlete* that they must remain on camera with the DCO via the IT system for the duration of the *Sample* Collection Session. The DCO shall also inform the *Athlete* that recording functions have been completely disabled.

K.4.5 The DCO shall then provide the *Athlete* with the package that includes Sample Collection Equipment, other supporting devices such as temperature monitoring strips, and applicable documentation. The DCO shall inform the *Athlete* to proceed with the Sample Collection Equipment to a suitable Sample collection location that is private and where the Sample Collection Session can continue. The DCO shall also ensure they are in a private location.

K.4.6 When the *Athlete* is positioned in the Sample Collection location where the Sample Collection Session will be conducted, the DCO, connected virtually via the IT system, shall instruct the *Athlete* to: a) Confirm if an *Athlete* representative is present with the *Athlete* in the Sample Collection location; b) Show the DCO on camera via the IT system the Sample Collection location selected where the *Sample* Collection Session will be conducted; and c) Confirm satisfactory audio and visual quality of the IT system used.

K.4.7 The DCO shall confirm to the *Athlete* that the DCO will also be on camera for the duration of the *Sample* Collection Session and that the *Sample* Collection Session is not being recorded.

K.4.8 The DCO shall then ask the *Athlete* to place the IT system in a location where the DCO will have a view of the *Athlete* (including upper body and hands) and have full view of the *Sample* Collection Equipment.

K.4.9 The *Athlete* shall place the content of the package with the *Sample* Collection Equipment, supporting devices and documentation on a steady surface in the *Sample* collection location in full view of the DCO.

K.4.10 The *Athlete* shall complete the '*Athlete* Information' part of the Sample collection documentation (either in paper or electronic) with the assistance of the DCO.

K.4.11 The DCO shall instruct the *Athlete* to select a collection vessel in accordance with Annex C.4.3. The DCO shall then ask the *Athlete* to apply a temperature monitoring strip to the outside of the collection vessel.

K.4.12 When the *Athlete* is ready to provide a urine *Sample*, the DCO shall ask the *Athlete* to move to the toilet area and show the DCO on camera the toilet area in which they will be providing their Sample. The DCO should direct the *Athlete* as to the best location for the IT system to be positioned during the Sample provision. Anything suspicious e.g., other urine Samples or doping paraphernalia in the toilet area with potential to compromise the Sample collection shall be documented in detail by the DCO.

K.4.13 The DCO shall also inform the *Athlete* that *Sample* provision will not be directly witnessed as

it normally would be, i.e., the DCO observing the urine *Sample* directly leaving their body, however, the *Athlete* will be continuously observed via the IT system in the toilet area. The camera shall be set in a position in the toilet area that provides the DCO with a full view of the *Athlete*'s upper body (i.e., waist to top of head) and arms while they are waiting to provide a *Sample* and/or during the *Sample* provision.

K.4.14 The *Athlete* shall be reminded of the importance to stay on camera during the sample provision and be advised of the possible *Consequences* of a Failure to Comply. Any loss of connection should be documented including exact time and duration, as well as any further re-connection attempts and explanations from the *Athlete*. If the *Athlete* does not remain visible in the camera field of view or the *Sample* once provided by the *Athlete* does not remain visible in the camera field of view and if the circumstances are deemed suspicious by the DCO, the DCO shall consider collecting an additional *Sample* from the *Athlete*. The DCO shall document the facts in a detailed report and report the circumstances to the Testing Authority.

K.4.15 Once the *Athlete* provides the required volume of urine, the DCO shall ask the *Athlete* to show them the collection vessel with the volume measurement scale on camera to validate that the Suitable Volume of Urine for Analysis has been provided. Where the volume of urine provided by the *Athlete* is insufficient, the DCO shall provide instructions to the *Athlete* to follow the partial Sample collection procedure in accordance with Annex E - Urine *Sample* – Insufficient Volume.

K.4.16 Once the lid of the collection vessel has been secured, the DCO shall then ask the *Athlete* whilst in the toilet area to show the temperature monitoring strip measurement on camera to allow the DCO to confirm the temperature of the urine *Sample*.

K.4.17 The *Athlete* shall exit the toilet area and return to the *Sample* collection location, ensuring they keep their *Sample* visible on camera. On return to the *Sample* collection location, the *Athlete* shall position the camera in the same location as it was at the start of the procedure so that their *Sample* are in full view of the DCO until the *Sample* is sealed.

K.4.18 The DCO shall guide the *Athlete* through the process of selecting and opening a *Sample* collection kit containing A and B bottles in accordance with Annex C.4.3 and Annex C.4.12. The *Athlete* shall show the DCO the *Sample* code numbers and the DCO should document them (and later confirm upon receipt of the *Sample*).

K.4.19 The division of the *Sample* into the A and B bottles and the sealing of the A and B bottles shall be conducted by the *Athlete* in full view of the DCO in accordance with Annex C.4.13 and C.4.14.

K.4.20 Once the *Athlete* has finished the sealing of the A and B bottles, the *Athlete* shall test the residual urine in the collection vessel to determine if the Sample has a Suitable Specific Gravity for Analysis with the assistance of the DCO. When the urine Sample does not meet the requirement for Suitable Specific Gravity for Analysis, the DCO shall provide instructions to the *Athlete* to follow the appropriate procedures in accordance with Annex F - Urine *Samples* that do not meet the requirement for Suitable Specific Gravity for Analysis.

K.4.21 The *Athlete* shall complete the *Sample* collection documentation with the assistance of the DCO. The *Athlete* and the DCO shall sign appropriate documentation to indicate their satisfaction that the documentation accurately reflects the details of the Sample Collection Session. The DCO shall ensure that the *Athlete* is advised to keep a copy of the *Sample*

collection documentation (if in paper) or that the *Athlete* receives a copy of the *Sample* collection documentation (if electronic).

K.4.22 Upon completion, the DCO shall ask the *Athlete* to pack their Sample, all Sample Collection Equipment and documentation and meet the DCO in the initial location where the *Athlete* was notified or an agreed upon location.

K.4.23 The *Athlete* shall remain on camera until they have concluded the Sample Collection Session, and they meet the DCO in-person.

K.4.24 The DCO, upon receiving the requested equipment and documentation from the *Athlete*, shall conduct a review of all Sample Collection Equipment, supporting devices and documentation, and confirm, in writing, that Sample collection documentation and corresponding *Sample*(s) are enclosed.

Definitions

Defined Terms from the *Code* and from the *ADSC*

ADAMS: The Anti-Doping Administration and Management System is a Web-based database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and WADA in their anti-doping operations in conjunction with data protection legislation.

Adverse Analytical Finding: A report from a WADA-accredited laboratory or other WADA- approved laboratory that, consistent with the International Standard for Laboratories, establishes in a *Sample* the presence of a Prohibited Substance or its Metabolites or Markers or evidence of the Use of a Prohibited Method.

Adverse Passport Finding: A report identified as an *Adverse Passport Finding* as described in the applicable International Standards.

Anti-Doping Organization: WADA or a Signatory that is responsible for adopting rules for initiating, implementing or enforcing any part of the Doping Control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other Major Event Organizations that conduct Testing at their Events, International Federations, and National Anti-Doping Organizations.

Anti-Doping Sport Code (ADSC): The Code, adopted by NADO Italia, implementing the *World Anti-Doping Code* and the *International Standards*.

Athlete: Any *Person* who Competes in sport under the aegis of the relevant International Federation and/or the Italian National Olympic Committee (CONI) and Italian Paralympic Committee (IPC).

Athlete Biological Passport: The program and methods of gathering and collating data as described in the International Standard for Testing and Investigations and International Standard for Laboratories.

Athlete Support Personnel: Any coach, trainer, manager, agent, team staff, official, medical, paramedical personnel, parent or any other Person working with, treating or assisting an *Athlete* participating in or preparing for sports Competition.

Attempt: Purposely engaging in conduct that constitutes a substantial step in a course of conduct planned to culminate in the commission of an anti-doping rule violation. Provided, however, there shall be no anti-doping rule violation based solely on an Attempt to commit a violation if the Person renounces the Attempt prior to it being discovered by a third party not involved in the Attempt.

Atypical Finding: A report from a WADA-accredited laboratory or other WADA-approved laboratory which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an *Adverse Analytical Finding*.

Atypical Passport Finding: A report described as an Atypical Passport Finding as described in the applicable International Standards.

CAS: The Court of Arbitration for Sport.

Code: The World Anti-Doping Code.

Competition: A single race, match, game or singular sport contest. For example, a basketball game or the finals of the Olympic 100-meter race in athletics. For stage races and other sport contests where prizes are awarded on a daily or other interim basis, the distinction between a Competition and an Event will be as provided in the rules of the applicable International Federation.

Consequences of Anti-Doping Rule Violations ("Consequences"): An *Athlete*'s or other Person's violation of an anti-doping rule may result in one or more of the following: (a) Disqualification means the *Athlete*'s results in a particular Competition or Event are invalidated, with all resulting Consequences including forfeiture of any medals, points and prizes; (b) Ineligibility means the *Athlete* or other Person is barred on account of an anti-doping rule violation for a specified period of time from participating in any Competition or other activity or funding as provided in *Code* Article 10.14; (c) Provisional Suspension means the *Athlete* or other Person is barred temporarily from participating in any Competition or activity prior to the final decision at a hearing conducted under *Code* Article 8; (d) Financial Consequences means a financial sanction imposed for an anti-doping rule violation or to recover costs associated with an anti-doping rule violation; and (e) Public Disclosure means the dissemination or distribution of information to the general public or Persons beyond those Persons entitled to earlier notification in accordance with *Code* Article 14. Teams in Team Sports may also be subject to Consequences as provided in *Code* Article 11.

Decision Limit: The value of the result for a threshold substance in a *Sample*, above which an *Adverse Analytical Finding* shall be reported, as defined in the International Standard for Laboratories.

Delegated Third Party: Any Person to which an Anti-Doping Organization delegates any aspect of Doping Control or anti-doping Education programs including, but not limited to, third parties or other Anti-Doping Organizations that conduct *Sample* collection or other Doping Control services or anti-doping Educational programs for the Anti-Doping Organization, or individuals serving as independent contractors who perform Doping Control services for the Anti-Doping Organization (e.g., non-employee Doping Control Officers or Chaperones).This definition does not include CAS.

Doping Control: All steps and processes from test distribution planning through to ultimate disposition of any appeal and the enforcement of Consequences, including all steps and processes in between, including but not limited to, Testing, investigation, whereabouts, TUEs, *Sample* collection and handling, laboratory analysis, *Results Management* and investigations or proceedings relating to violations of *Code* Article 10.14 (Status During Ineligibility or Provisional Suspension).

Education: The process of learning to instill values and develop behaviors that foster and protect the spirit of sport, and to prevent intentional and unintentional doping.

Event: A series of individual Competitions conducted together under one ruling body (e.g., the Olympic Games, World Championships of an International Federation, or Pan American Games).

Event Venues: Those venues so designated by the ruling body for the Event.

In-Competition: The period commencing at 11:59 p.m. on the day before a Competition in which the *Athlete* is scheduled to participate through the end of such Competition and the *Sample* collection process related to such Competition. Provided, however, WADA may approve, for a particular sport, an alternative definition if an International Federation provides a compelling justification that a different definition is necessary for its sport; upon such approval by WADA, the alternative definition shall be followed by all *Major Event Organizations* for that particular sport.

Independent Observer Program: A team of observers and/or auditors, under the supervision of WADA, who observe and provide guidance on the Doping Control process prior to or during certain Events and report on their observations as part of WADA's compliance monitoring program.

Ineligibility: See Consequences of Anti-Doping Rule Violations above.

International Event: An Event or Competition where the International Olympic Committee, the International Paralympic Committee, an International Federation, a Major Event Organization, or another international sport organization is the ruling body for the Event or appoints the technical officials for the Event.

International-Level Athlete: *Athlete*s who compete in sport at the international level, as defined by each International Federation, consistent with the International Standard for Testing and Investigations.

International Standard: A standard adopted by WADA in support of the Code. Compliance with an International Standard (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures addressed by the International Standard were performed properly. International Standards shall include any Technical Documents issued pursuant to the International Standard.

Major Event Organizations: The continental associations of *National Olympic Committees* and other international multisport organizations that function as the ruling body for any continental, regional or other International *Event*.

Marker: A compound, group of compounds or biological variable(s) that indicates the Use of a Prohibited Substance or Prohibited Method.

Minor: A natural Person who has not reached the age of eighteen years.

National Anti-Doping Organization: The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of *Sample*s, manage test results and conduct *Results Management* at the national level. If this designation has not been made by the competent public authority(ies), the entity shall be the country's National Olympic Committee or its designee.

National Event: A sport Event or Competition involving International- or National-Level *Athlete*s that is not an International Event.

National-Level Athlete: An *Athlete* included in the national RTP; Athletes included in the Club Olimpico (who receive funding from Sports movement); an *Athlete* who currently or in the last six (6) months has represented Italy at senior level; an *Athlete* who has been selected to represent Italy in International *Events* or Competitions, not classified as International-Level *Athlete* by the relevant International Federation.

National Olympic Committee: The organization recognized by the International Olympic Committee. The term National Olympic Committee shall also include the National Sport Confederation in those countries where the National Sport Confederation assumes typical National Olympic Committee responsibilities in the anti-doping area. In Italy, the *National Olympic Committee* is *Comitato Olimpico Nazionale Italiano* (CONI).

Out-of-Competition: Any period which is not In-Competition.

Person: A natural Person or an organization or other entity.

Prohibited Method: Any method so described on the Prohibited List.

Prohibited Substance: Any substance, or class of substances, so described on the Prohibited List.

Protected Person: An *Athlete* or other natural Person who at the time of the anti-doping rule violation: (i) has not reached the age of sixteen (16) years; (ii) has not reached the age of eighteen (18) years and is not included in any *Registered Testing Pool* and has never competed in any International Event in an open category; or (iii) for reasons other than age, has been determined to lack legal capacity under applicable national legislation.

Provisional Suspension: See Consequences of Anti-Doping Rule Violations above.

Recreational Athlete: In Italy, *Recreational Athlete* is any *Person* member of a Sport Promotion Entity, or any *Person* who takes part in local *Competitions* or competes at lower level *Team Sports*.
In any case, *Recreational Athlete* does not include who, within the five (5) years prior to committing any anti-doping rule violation: (i) has been an *International-Level Athlete* (as defined by each International Federation consistent with the *International Standard* for *Testing* and Investigations) or *National-Level Athlete* (as defined by NADO Italia or other *National Anti-Doping Organization* consistent with the *International Standard* for *Testing* and Investigations); (i) has represented Italy or any other country in an *International Event* in an open category; (iii) or has been included within any *Registered Testing Pool* or other whereabouts information pool maintained by any International Federation, NADO Italia or other *National Anti-Doping Organization*.

Registered Testing Pool: The pool of highest-priority *Athlete*s established separately at the international level by International Federations and at the national level by National Anti-Doping Organizations, who are subject to focused In-Competition and Out-of-Competition Testing as part of that International Federation's or National Anti-Doping Organization's Test Distribution Plan and therefore are required to provide whereabouts information as provided in Article 5.5 and the *International Standard for Testing and Investigations*. In Italy, NADO Italia's *Registered Testing Pool* is defined as set out in *ADSC* Article 6.5.

Results Management: The process encompassing the timeframe between notification as per Article 5 of the International Standard for Results Management, or in certain cases (e.g., Atypical Finding, *Athlete Biological Passport*, whereabouts failure), such pre-notification steps expressly provided for in Article 5 of the *International Standard for Results Management*, through the charge until the final resolution of the matter, including the end of the hearing process at first instance or on appeal (if an appeal was lodged).

Sample or Specimen: Any biological material collected for the purposes of Doping Control.

Signatories: Those entities accepting the *Code* and agreeing to implement the *Code*, as provided in *Code* Article 23.

Substantial Assistance: For purposes of *Code* Article 10.7.1, a Person providing *Substantial Assistance* must: (1) fully disclose in a signed written statement or recorded interview all information he or she possesses in relation to anti-doping rule violations or other proceeding described in *Code* Article 10.7.1.1 and (2) fully cooperate with the investigation and adjudication of any case or matter related to that information, including, for example, presenting testimony at a hearing if requested to do so by an Anti-Doping Organization or hearing panel. Further, the information provided must be credible and must comprise an important part of any case or proceeding which is initiated or, if no case or proceeding is initiated, must have provided a sufficient basis on which a case or proceeding could have been brought.

Tampering: Intentional conduct which subverts the Doping Control process but which would not otherwise be included in the definition of Prohibited Methods. *Tampering* shall include, without limitation, offering or accepting a bribe to perform or fail to perform an act, preventing the collection of a Sample, affecting or making impossible the analysis of a Sample, falsifying documents submitted to an Anti-Doping Organization or TUE committee or hearing panel, procuring false testimony from witnesses, committing any other fraudulent act upon the Anti- Doping Organization or hearing body to affect Results Management or the imposition of Consequences, and any other similar intentional interference or Attempted interference with any aspect of Doping Control.

Target Testing: Selection of specific *Athlete*s for Testing based on criteria set forth in the *International Standard for Testing and Investigations*.

Team Sport: A sport in which the substitution of players is permitted during a *Competition*.

Technical Document: A document adopted and published by WADA from time to time containing mandatory technical requirements on specific anti-doping topics as set forth in an *International Standard*.

Testing: The parts of the Doping Control process involving test distribution planning, Sample collection, Sample handling, and Sample transport to the Laboratory.

WADA: The World Anti-Doping Agency.

Defined terms from the International Standard for Laboratories (ISL):

ABP Laboratory: A laboratory not otherwise accredited by *WADA*, which is approved by *WADA* to apply Analytical Methods and processes in support of the hematological module of the *ABP* program and in accordance with the criteria for approval of non-accredited laboratories for the *ABP*.

Analytical Testing: The parts of the Doping Control process performed at the Laboratory, which include Sample handling, analysis and reporting of results.

Analytical Testing Procedure: A Fit-for-Purpose procedure, as demonstrated through method validation, and used to detect, identify and/or quantify Analytes in a Sample for *Doping Control* purposes in accordance with the ISL and relevant *Technical Document(s)*, Technical Letter(s) or Laboratory Guidelines. An Analytical *Testing* Procedure is also referred to or known as an Analytical Method or Test Method.

***Athlete* Passport Management Unit (APMU)**: A unit composed of a Person or Persons that is responsible for the timely management of *Athlete* Biological Passports in ADAMS on behalf of the Passport Custodian.

Confirmation Procedure (CP): An Analytical Testing Procedure that has the purpose of confirming the presence and/or, when applicable, confirming the concentration/ratio/score and/or establishing the origin (exogenous or endogenous) of one or more specific Prohibited Substances, Metabolite(s) of a Prohibited Substance, or Marker(s) of the Use of a Prohibited Substance or Prohibited Method in a Sample.

Further Analysis: Further Analysis, as this term is used in the ISL, occurs when a Laboratory conducts additional analysis on an "A" *Sample* or a "B" *Sample* after an analytical result for that "A" *Sample* or that "B" *Sample* has been reported by the Laboratory.

Laboratory: (A) WADA-accredited laboratory applying Test Methods and processes to provide evidentiary data for the detection and/or identification of Prohibited Substances or Prohibited Methods on the Prohibited List and, if applicable, quantification of a Threshold Substance in Samples of urine and other biological matrices in the context of Doping Control activities.

WADA-Approved Laboratory(-ies) for the *Athlete* Biological Passport: Laboratory(-ies) not otherwise accredited by WADA which apply Analytical Methods and processes in support of the hematological module of the ABP program and in accordance with the criteria for approval of non-accredited laboratories for the ABP.

Defined Terms from the International Standard for Results Management (ISRM):

Adaptive Model: A mathematical model designed to identify unusual longitudinal results from *Athlete*s. The model calculates the probability of a longitudinal profile of *Marker* values, assuming that the *Athlete* has a normal physiological condition.

Failure to Comply: A term used to describe anti-doping rule violations under *Code* Articles 2.3 and/or 2.5.

Filing Failure: A failure by the *Athlete* (or by a third party to whom the *Athlete* has delegated the task) to make an accurate and complete Whereabouts Filing that enables the *Athlete* to be located for Testing at the times and locations set out in the Whereabouts Filing or to update that Whereabouts Filing where necessary to ensure that it remains accurate and complete, all in accordance with Article 4.8 of the International Standard for Testing and Investigations and Annex B of the International Standard for Results Management.

Missed Test: A failure by the *Athlete* to be available for Testing at the location and time specified in the 60-minute time slot identified in their Whereabouts Filing for the day in question, in accordance with Article 4.8 of the International Standard for Testing and Investigations and Annex B of the International Standard for Results Management.

Passport Custodian: The Anti-Doping Organization responsible for Results Management of that *Athlete*'s Passport and for sharing any relevant information associated to that *Athlete*'s Passport with other Anti-Doping Organization(s).

Results Management Authority: The Anti-Doping Organization responsible for conducting Results Management in a given case.

Whereabouts Failure: A Filing Failure or a Missed Test.

Defined Terms from the International Standard for the Protection of Privacy and Personal Information (ISPPPI):

Processing (and its cognates, Process and Processed): Collecting, accessing, retaining, storing, disclosing, transferring, transmitting, amending, deleting or otherwise making use of Personal Information.

Defined Terms specific to the International Standard for Testing and Investigations (ISTI):

Blood Collection Officer (or BCO): An official who is qualified and has been authorized by the Sample Collection Authority to collect a blood Sample from an *Athlete*.

Chain of Custody: The sequence of individuals or organizations who have responsibility for the custody of a Sample from the provision of the Sample until the Sample has been delivered to the Laboratory for analysis.

Chaperone: An official who is suitably trained and authorized by the Sample Collection Authority to carry out specific duties including one or more of the following (at the election of the Sample Collection Authority): notification of the *Athlete* selected for Sample collection; accompanying and observing the *Athlete* until arrival at the Doping Control Station; accompanying and/or observing *Athlete*s who are present in the Doping Control Station; and/or witnessing and verifying the provision of the Sample where the training specifically qualifies them to do so.

Code Article 2.4 Whereabouts Requirements: The whereabouts requirements set out in Article 4.8 of the International Standard for Testing and Investigations, which apply to *Athlete*s who are included in the *Registered Testing Pool* of an International Federation or a

National Anti-Doping Organization.

Doping Control Coordinator: An Anti-Doping Organization or a Delegated Third Party that coordinates any aspect of Doping Control on behalf of an Anti-Doping Organization. The Anti- Doping Organization always remains ultimately responsible under the Code for compliance with the requirements of the ISTI, ISTUE, ISPPPI and ISRM.

Doping Control Officer (or DCO): An official who has been trained and authorized by the Sample Collection Authority to carry out the responsibilities given to DCOs in the International Standard for Testing and Investigations.

Doping Control Station: The location where the Sample Collection Session will be conducted in accordance with Article 6.3.2 of the International Standard for Testing and Investigations.

In-Competition Date: As described in Article 4.8.8.4 of the International Standard for Testing and Investigations.

No Advance Notice Testing: Sample collection that takes place with no advance warning to the *Athlete* and where the *Athlete* is continuously chaperoned from the moment of notification through Sample provision.

Random Selection: Selection of *Athlete*s for Testing which is not *Target Testing*.

Risk Assessment: The assessment of risk of doping in a sport or sports discipline conducted by an Anti-Doping Organization in accordance with Article 4.2 of the International Standard for Testing and Investigations.

Sample Collection Authority: The organization that is responsible for the collection of Samples in compliance with the requirements of the International Standard for Testing and Investigations, whether (1) the Testing Authority itself; or (2) a Delegated Third Party to whom the authority to conduct Testing has been granted or sub-contracted. The Testing Authority always remains ultimately responsible under the Code for compliance with the requirements of the International Standard for Testing and Investigations relating to collection of Samples.

Sample Collection Equipment: A and B bottles, kits or containers, collection vessels, tubes or other apparatus used to collect, hold or store the Sample at any time during and after the Sample Collection Session that shall meet the requirements of Article 6.3.4 of the International Standard for Testing and Investigations.

Sample Collection Personnel: A collective term for qualified officials authorized by the Sample Collection Authority to carry out or assist with duties during the Sample Collection Session.

Sample Collection Session: All of the sequential activities that directly involve the *Athlete* from the point that initial contact is made until the *Athlete* leaves the Doping Control Station after having provided their Sample(s).

Suitable Specific Gravity for Analysis: For Samples with a minimum volume of 90mL

and less than 150mL, specific gravity measured at 1.005 or higher with a refractometer, or 1.010 or higher with lab sticks. For Samples with a volume of 150mL and above, specific gravity measured at 1.003 or higher with a refractometer only.

Suitable Volume of Urine for Analysis: A minimum of 90 mL, whether the Laboratory will be analyzing the Sample for all or only some Prohibited Substances or Prohibited Methods.

Tamper Evident: Refers to having one or more indicators or barriers to entry incorporated into or, if applicable, included with the Sample Collection Equipment, which, if breached or missing or otherwise compromised, can provide visible evidence that *Tampering* or Attempted *Tampering* of Sample Collection Equipment has occurred.

Team Activity/Activities: Sporting activities carried out by *Athlete*s on a collective basis as part of a team (e.g., training, travelling, tactical sessions) or under the supervision of the team (e.g., treatment by a team doctor).

Technical Document for Sport Specific Analysis (TDSSA): The Technical Document which establishes minimum levels of analysis that Anti-Doping Organizations must apply to sports and sport disciplines for certain Prohibited Substances and/or Prohibited Methods, which are most likely to be abused in particular sports and sport disciplines.

Test(s): Any combination of Sample(s) collected (and analyzed) from a single *Athlete* in a single Sample Collection Session.

Test Distribution Plan (TDP): A document written by an Anti-Doping Organization that plans Testing on *Athlete*s, in accordance with the requirements of Article 4 of the International Standard for Testing and Investigations.

Testing Authority: The Anti-Doping Organization that authorizes Testing on *Athlete*s it has authority over. It may authorize a Delegated Third Party to conduct Testing pursuant to the authority of and in accordance with the rules of the Anti-Doping Organization. Such authorization shall be documented. The Anti-Doping Organization authorizing Testing remains the Testing Authority and ultimately responsible under the Code to ensure the Delegated Third Party conducting the Testing does so in compliance with the requirements of the International Standard for Testing and Investigations.

Unsuccessful Attempt Report: A detailed report of an unsuccessful attempt to collect a Sample from an *Athlete* in a *Registered Testing Pool* or Testing pool setting out the date of the attempt, the location visited, the exact arrival and departure times at the location, the steps taken at the location to try to find the *Athlete* (including details of any contact made with third parties), and any other relevant details about the attempt.

Whereabouts Filing: Information provided by or on behalf of an *Athlete* in a *Registered Testing Pool* that sets out the *Athlete*'s whereabouts during the current and/or following quarter, in accordance with Article 4.8 of the International Standard for Testing and Investigations.